COVID-19 vaccine

Page semi-protected
Source: Wikipedia, the free encyclopedia.
(Redirected from
COVID-19 vaccines
)

COVID-19 vaccine
Vaccine description
TargetSARS-CoV-2
Vaccine typemRNA, viral, inactivated, protein
Clinical data
Routes of
administration
Intramuscular
ATC code
Identifiers
ChemSpider
  • none

How COVID‑19 vaccines work. The video shows the process of vaccination, from injection with RNA or viral vector vaccines, to uptake and translation, and on to immune system stimulation and effect.

A COVID‑19 vaccine is a

acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID‑19
).

Prior to the

Janssen COVID‑19 vaccine.[3] However, immunity from the vaccines has been found to wane over time, requiring people to get booster doses of the vaccine to maintain protection against COVID‑19.[3]

The COVID‑19 vaccines are widely credited for their role in reducing the spread of COVID‑19 and reducing the severity and death caused by COVID‑19.[3][6] According to a June 2022 study, COVID‑19 vaccines prevented an additional 14.4 to 19.8 million deaths in 185 countries and territories from 8 December 2020 to 8 December 2021.[7][8] Many countries implemented phased distribution plans that prioritized those at highest risk of complications, such as the elderly, and those at high risk of exposure and transmission, such as healthcare workers.[9][10]

Common side effects of COVID‑19 vaccines include soreness, redness, rash, inflammation at the injection site, fatigue, headache, myalgia (muscle pain), and arthralgia (joint pain), which resolve without medical treatment within a few days.[11][12] COVID‑19 vaccination is safe for people who are pregnant or are breastfeeding.[13]

As of 1 February 2024, 13.57 billion doses of COVID‑19 vaccines have been administered worldwide, based on official reports from national public health agencies.[14] By December 2020, more than 10 billion vaccine doses had been preordered by countries,[15] with about half of the doses purchased by high-income countries comprising 14% of the world's population.[16]

Despite the extremely rapid development of effective

developing countries.[17][18]

The 2023 Nobel Prize in Physiology or Medicine was awarded to Katalin Karikó and Drew Weissman for the development of effective mRNA vaccines against COVID-19.[19][20][21]

Background

  • COVID‑19 vaccine doses administered by continent as of October 11, 2021. For vaccines that require multiple doses, each individual dose is counted. As the same person may receive more than one dose, the number of doses can be higher than the number of people in the population.
    COVID‑19 vaccine doses administered by continent as of October 11, 2021. For vaccines that require multiple doses, each individual dose is counted. As the same person may receive more than one dose, the number of doses can be higher than the number of people in the population.
  • Map showing share of population fully vaccinated against COVID-19 relative to a country's total population[note 1]
    Map showing share of population fully vaccinated against COVID-19 relative to a country's total population[note 1]
A US airman receiving a COVID‑19 vaccine, December 2020
Map of countries by approval status
  Approved for general use, mass vaccination underway
  EUA (or equivalent) granted, mass vaccination underway
  EUA granted, mass vaccination planned
  No data available

Prior to COVID‑19, a vaccine for an infectious disease had never been produced in less than several years – and no vaccine existed for preventing a

Middle East respiratory syndrome (MERS). Vaccines against SARS[24] and MERS[25] have been tested in non-human animals
.

According to studies published in 2005 and 2006, the identification and development of novel vaccines and medicines to treat SARS was a priority for governments and public health agencies around the world at that time.[26][27][28] There is no cure or protective vaccine proven to be safe and effective against SARS in humans.[29][30] There is also no proven vaccine against MERS.[31] When MERS became prevalent, it was believed that existing SARS research might provide a useful template for developing vaccines and therapeutics against a MERS-CoV infection.[29][32] As of March 2020, there was one (DNA-based) MERS vaccine that completed Phase I clinical trials in humans,[33] and three others in progress, all being viral-vectored vaccines: two adenoviral-vectored (ChAdOx1-MERS, BVRS-GamVac) and one MVA-vectored (MVA-MERS-S).[34]

Vaccines that use an inactive or weakened virus that has been grown in eggs typically take more than a decade to develop.[35][36] In contrast, mRNA is a molecule that can be made quickly, and research on mRNA to fight diseases was begun decades before the COVID‑19 pandemic by scientists such as Drew Weissman and Katalin Karikó, who tested on mice. Moderna began human testing of an mRNA vaccine in 2015.[35] Viral vector vaccines were also developed for the COVID‑19 pandemic after the technology was previously cleared for Ebola.[35]

As multiple COVID‑19 vaccines have been authorized or licensed for use, real-world vaccine effectiveness (RWE) is being assessed using case control and observational studies.[37][38] A study is investigating the long-lasting protection against SARS-CoV-2 provided by the mRNA vaccines.[39][40]

Vaccine technologies

RNA vaccine; (2) subunit vaccine; (3) viral vector
vaccine
Vaccine platforms that are being employed for SARS-CoV-2. Whole-virus vaccines include both attenuated and inactivated forms of the virus. Protein and peptide subunit vaccines are usually combined with an adjuvant in order to enhance immunogenicity. The main emphasis in SARS-CoV-2 vaccine development has been on using the whole spike protein in its trimeric form, or components of it, such as the RBD region. Multiple non-replicating viral vector vaccines have been developed, particularly focused on adenovirus, while there has been less emphasis on the replicating viral vector constructs.[41]

As of July 2021, at least nine different technology platforms were under research and development to create an effective vaccine against COVID‑19.

nucleocapsid, because they also induce a robust T-cell response and their genes are more conserved and recombine less frequently (compared to Spike).[45][46][47] Future generations of COVID‑19 vaccines that may target more conserved genomic regions will also act as insurance against the manifestation of catastrophic scenarios concerning the future evolutionary path of SARS-CoV-2, or any similar coronavirus epidemic/pandemic.[48]

Platforms developed in 2020 involved

Many vaccine technologies being developed for COVID‑19 are not like

pregnant women, and people with weakened immune systems.[42][49]

mRNA vaccines

RNA vaccine. Messenger RNA contained in the vaccine enters cells and is translated
into foreign proteins, which trigger an immune response.

Several COVID‑19 vaccines, such as the

lipid nanoparticles, which protect the RNA strands and help their absorption into the cells.[52][53][54][55]

RNA vaccines are the first COVID‑19 vaccines to be authorized in the United Kingdom, the United States, and the European Union.

CVnCoV RNA vaccine from CureVac failed in clinical trials.[63]

Severe allergic reactions are rare. In December 2020, 1,893,360 first doses of Pfizer–BioNTech COVID‑19 vaccine administration resulted in 175 cases of severe allergic reactions, of which 21 were anaphylaxis.[64] For 4,041,396 Moderna COVID‑19 vaccine dose administrations in December 2020 and January 2021, only ten cases of anaphylaxis were reported.[64] Lipid nanoparticles (LNPs) were most likely responsible for the allergic reactions.[64]

Adenovirus vector vaccines

These vaccines are examples of non-replicating viral vector vaccines using an adenovirus shell containing DNA that encodes a SARS‑CoV‑2 protein.[65][66] The viral vector-based vaccines against COVID‑19 are non-replicating, meaning that they do not make new virus particles but rather produce only the antigen that elicits a systemic immune response.[65]

Authorized

Janssen COVID‑19 vaccine.[71][72]

Convidecia and Janssen are both one-shot vaccines that offer less complicated logistics and can be stored under ordinary refrigeration for several months.[73][74]

Sputnik V uses Ad26 for its first dose, which is the same as Janssen's only dose, and Ad5 for the second dose, which is the same as Convidecia's only dose.[75]

In August 2021, the developers of Sputnik V proposed, in view of the Delta case surge, that Pfizer test the Ad26 component (termed its 'Light' version)[76] as a booster shot.[77]

Inactivated virus vaccines

Inactivated vaccines consist of virus particles that are grown in culture and then killed using a method such as heat or formaldehyde to lose disease-producing capacity while still stimulating an immune response.[78]

Inactivated virus vaccines authorized in China include the Chinese

Valneva COVID‑19 vaccine.[86][unreliable source?][87]

Subunit vaccines

Subunit vaccines present one or more antigens without introducing whole pathogen particles. The antigens involved are often protein subunits, but they can be any molecule fragment of the pathogen.[88]

The authorized vaccines of this type are the

Bimervax was approved for use as a booster vaccine in the European Union in March 2023.[96][97]

The V451 vaccine was in clinical trials that were terminated after it was found that the vaccine may potentially cause incorrect results for subsequent HIV testing.[98][99][100]

Virus-like particle vaccines

The authorized vaccines of this type include the

Novavax COVID‑19 vaccine.[17][101]

Other types

Additional types of vaccines that are in clinical trials include multiple

vesicular stomatitis virus displaying the SARS‑CoV‑2 spike protein.[110]

Scientists investigated whether existing vaccines for unrelated conditions could prime the immune system and lessen the severity of COVID‑19 infections.[111] There is experimental evidence that the BCG vaccine for tuberculosis has non-specific effects on the immune system, but there is no evidence that this vaccine is effective against COVID‑19.[112]

List of authorized vaccines

Delivery methods

All coronavirus vaccines are administered by injection. However, various other types of vaccine delivery methods have been studied for future coronavirus vaccines.

Intranasal

Intranasal vaccines target

immune factors, such as IgA.[114] In addition to inhibiting the virus, nasal vaccines provide ease of administration because no needles (or needle phobia) are involved.[115][116]

A variety of intranasal COVID‑19 vaccines are undergoing clinical trials. One is in use in China.[117] Examples include a vaccine candidate that uses a modified avian virus as a vector to target SARS-CoV-2 spike proteins and an mRNA vaccine delivered via a nasal nanoparticle spray.[118] In September 2022, India and China approved the two first nasal COVID‑19 vaccines (iNCOVACC and Convidecia), which may (as boosters)[119] also reduce transmission[120][121] (potentially via sterilizing immunity).[120]

Autologous

Aivita Biomedical is developing an experimental autologous dendritic cell COVID‑19 vaccine kit where the vaccine is prepared and incubated at the point-of-care using cells from the intended recipient.[122] The vaccine is undergoing small phase I and phase II clinical studies.[122][123][124]

Universal vaccine

A universal coronavirus vaccine would be effective against all coronaviruses and possibly other viruses.

NIAID director Anthony Fauci, virologist Jeffery K. Taubenberger, and David M. Morens.[127] In March 2022, the White House released the "National COVID‑19 Preparedness Plan", which recommended accelerating the development of a universal coronavirus vaccine.[128]

One attempt at such a vaccine is being developed at the Walter Reed Army Institute of Research. It uses a spike ferritin-based nanoparticle (SpFN). This vaccine began a Phase I clinical trial in April 2022.[129]

Another strategy is to attach vaccine fragments from multiple strains to a nanoparticle scaffold. One theory is that a broader range of strains can be vaccinated against by targeting the receptor-binding domain, rather than the whole spike protein.[130]

Formulation

As of September 2020, eleven of the vaccine candidates in clinical development use

immunological adjuvant is a substance formulated with a vaccine to elevate the immune response to an antigen, such as the COVID‑19 virus or influenza virus.[131] Specifically, an adjuvant may be used in formulating a COVID‑19 vaccine candidate to boost its immunogenicity and efficacy to reduce or prevent COVID‑19 infection in vaccinated individuals.[131][132] Adjuvants used in COVID‑19 vaccine formulation may be particularly effective for technologies using the inactivated COVID‑19 virus and recombinant protein-based or vector-based vaccines.[132] Aluminum salts, known as "alum", were the first adjuvant used for licensed vaccines and are the adjuvant of choice in some 80% of adjuvanted vaccines.[132] The alum adjuvant initiates diverse molecular and cellular mechanisms to enhance immunogenicity, including the release of proinflammatory cytokines.[131][132]

Planning and development

Since January 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments.[42]

Multiple steps along the entire development path are evaluated, including:[22][133]

  • the level of acceptable toxicity of the vaccine (its safety),
  • targeting vulnerable populations,
  • the need for vaccine efficacy breakthroughs,
  • the duration of vaccination protection,
  • special delivery systems (such as oral or nasal, rather than by injection),
  • dose regimen,
  • stability and storage characteristics,
  • emergency use authorization before formal licensing,
  • optimal manufacturing for scaling to billions of doses, and
  • dissemination of the licensed vaccine.

Challenges

There have been several unique challenges with COVID‑19 vaccine development.

Public health programs[who?] have been described as "[a] race to vaccinate individuals" with the early wave vaccines.[134]

Timelines for conducting clinical research – normally a sequential process requiring years – are being compressed into safety, efficacy, and dosing trials running simultaneously over months, potentially compromising safety assurance.[135][136] For example, Chinese vaccine developers and the Chinese Center for Disease Control and Prevention began their efforts in January 2020,[137] and by March they were pursuing numerous candidates on short timelines.[135][138]

The rapid development and urgency of producing a vaccine for the COVID‑19 pandemic were expected to increase the risks and failure rate of delivering a safe, effective vaccine.[49][50][139] Additionally, research at universities is obstructed by physical distancing and the closing of laboratories.[140][141]

Vaccines must progress through several phases of clinical trials to test for safety, immunogenicity, effectiveness, dose levels, and adverse effects of the candidate vaccine.[142][143] Vaccine developers have to invest resources internationally to find enough participants for Phase II–III clinical trials when the virus has proved to be a "moving target" of changing transmission rates across and within countries, forcing companies to compete for trial participants.[144]

Clinical trial organizers may also encounter people unwilling to be vaccinated due to vaccine hesitancy[145] or disbelief in the science of the vaccine technology and its ability to prevent infection.[146] As new vaccines are developed during the COVID‑19 pandemic, licensure of COVID‑19 vaccine candidates[who?] requires submission of a full dossier of information on development and manufacturing quality.[147][148][149]

Organizations

Internationally, the

Access to COVID‑19 Tools Accelerator is a G20 and World Health Organization (WHO) initiative announced in April 2020.[150][151] It is a cross-discipline support structure to enable partners to share resources and knowledge. It comprises four pillars, each managed by two to three collaborating partners: Vaccines (also called "COVAX"), Diagnostics, Therapeutics, and Health Systems Connector.[152] The WHO's April 2020 "R&D Blueprint (for the) novel Coronavirus" documented a "large, international, multi-site, individually randomized controlled clinical trial" to allow "the concurrent evaluation of the benefits and risks of each promising candidate vaccine within 3–6 months of it being made available for the trial." The WHO vaccine coalition will prioritize which vaccines should go into Phase II and III clinical trials and determine harmonized Phase III protocols for all vaccines achieving the pivotal trial stage.[153]

National governments have also been involved in vaccine development. Canada announced funding for 96 projects for the development and production of vaccines at Canadian companies and universities, with plans to establish a "vaccine bank" that could be used if another coronavirus outbreak occurs,[154] support clinical trials, and develop manufacturing and supply chains for vaccines.[155]

China provided low-rate loans to one vaccine developer through its central bank and "quickly made land available for the company" to build production plants.[136] Three Chinese vaccine companies and research institutes are supported by the government for financing research, conducting clinical trials, and manufacturing.[156]

The United Kingdom government formed a COVID‑19 vaccine task force in April 2020 to stimulate local efforts for accelerated development of a vaccine through collaborations between industries, universities, and government agencies. The UK's Vaccine Taskforce contributed to every phase of development, from research to manufacturing.[157]

In the United States, the Biomedical Advanced Research and Development Authority (BARDA), a federal agency funding disease-fighting technology, announced investments to support American COVID‑19 vaccine development and the manufacturing of the most promising candidates.[136][158] In May 2020, the government announced funding for a fast-track program called Operation Warp Speed.[159][160] By March 2021, BARDA had funded an estimated $19.3 billion in COVID‑19 vaccine development.[161]

Large pharmaceutical companies with experience in making vaccines at scale, including

GlaxoSmithKline (GSK), formed alliances with biotechnology companies, governments, and universities to accelerate progress toward effective vaccines.[136][135]

Clinical research


COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness, and safety. As of November 2022, 40 vaccines are authorized by at least one national regulatory authority for public use:[162][163]

As of June 2022, 353 vaccine candidates are in various stages of development, with 135 in clinical research, including 38 in phase I trials, 32 in phase I–II trials, 39 in phase III trials, and 9 in phase IV development.[162]

Post-vaccination complications

Post-vaccination embolic and thrombotic events, termed

Janssen COVID‑19 vaccine (Johnson & Johnson), leading to the suspension of its use until its safety had been reassessed.[176] On 5 May 2022 the FDA posted a bulletin limiting the use of the Janssen Vaccine to very specific cases due to further reassessment of the risks of TTS, although the FDA also stated in the same bulletin that the benefits of the vaccine outweigh the risks.[177]

In April 2021,
AstraZeneca and the European Medicines Agency (EMA) updated their information for healthcare professionals about AZD1222, saying it is "considered plausible" that there is a causal relationship between the vaccination and the occurrence of thrombosis in combination with thrombocytopenia and that, "although such adverse reactions are very rare, they exceeded what would be expected in the general population".[175][178][179][180]

History


NIAID
lab freezer (30 January 2020)

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the virus that causes COVID-19, was isolated in late 2019.[181] Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten the development of a preventive COVID-19 vaccine.[182][183][184] Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments.[185] By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection.[183][186][187][188] According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.[182][185]

In February 2020, the World Health Organization (WHO) said it did not expect a vaccine against SARS‑CoV‑2 to become available in less than 18 months.[189] Virologist Paul Offit commented that, in hindsight, the development of a safe and effective vaccine within 11 months was a remarkable feat.[190] The rapidly growing infection rate of COVID‑19 worldwide during 2020 stimulated international alliances and government efforts to urgently organize resources to make multiple vaccines on shortened timelines,[191] with four vaccine candidates entering human evaluation in March (see COVID-19 vaccine § Trial and authorization status).[182][192]

On 24 June 2020, China approved the CanSino vaccine for limited use in the military and two inactivated virus vaccines for emergency use in high-risk occupations.[193] On 11 August 2020, Russia announced the approval of its Sputnik V vaccine for emergency use, though one month later only small amounts of the vaccine had been distributed for use outside of the phase 3 trial.[194]

The Pfizer–BioNTech partnership submitted an

elasomeran), the Moderna vaccine.[206][207][208][209]

On 31 March 2021, the Russian government announced that they had registered the first COVID‑19 vaccine for animals.[210] Named Carnivac-Cov, it is an inactivated vaccine for carnivorous animals, including pets, aimed at preventing mutations that occur during the interspecies transmission of SARS-CoV-2.[211]

In October 2022, China began administering an oral vaccine developed by CanSino Biologics using its adenovirus model.[212]

Despite the availability of
developing countries, to dampen further waves of the pandemic.[213][214]

In November 2021, the full nucleotide sequences of the AstraZeneca and Pfizer/BioNTech vaccines were released by the UK Medicines and Healthcare products Regulatory Agency in response to a freedom of information request.[215][216]

Effectiveness

Death rates from COVID-19 for unvaccinated Americans substantially exceeded those who were vaccinated, with bivalent boosters further reducing the death rate.[217]

Evidence from vaccine use during the pandemic shows vaccination can reduce infection and is most effective at preventing severe COVID-19 symptoms and death, but is less good at preventing mild COVID-19. Efficacy wanes over time but can be maintained with boosters.[218] In 2021, the CDC reported that unvaccinated people were 10 times more likely to be hospitalized and 11 times more likely to die than fully vaccinated people.[219][220]

The CDC reported that vaccine effectiveness fell from 91% against Alpha to 66% against Delta.[221] One expert stated that "those who are infected following vaccination are still not getting sick and not dying like was happening before vaccination."[222] By late August 2021, the Delta variant accounted for 99 percent of U.S. cases and was found to double the risk of severe illness and hospitalization for those not yet vaccinated.[223]

In November 2021, a study by the

ECDC estimated that 470,000 lives over the age of 60 had been saved since the start of the vaccination roll-out in the European region.[224]

On 10 December 2021, the UK Health Security Agency reported that early data indicated a 20- to 40-fold reduction in neutralizing activity for Omicron by sera from Pfizer 2-dose vaccinees relative to earlier strains. After a booster dose (usually with an mRNA vaccine),[225] vaccine effectiveness against symptomatic disease was at 70%–75%, and the effectiveness against severe disease was expected to be higher.[226]

According to early December 2021 CDC data, "unvaccinated adults were about 97 times more likely to die from COVID-19 than fully vaccinated people who had received boosters".[227]

A meta-analysis looking into COVID-19 vaccine differences in immunosuppressed individuals found that people with a weakened immune system are less able to produce neutralizing antibodies. For example, organ transplant recipients need three vaccines to achieve seroconversion.[228] A study on the serologic response to mRNA vaccines among patients with lymphoma, leukemia, and myeloma found that one-quarter of patients did not produce measurable antibodies, varying by cancer type.[229]

In February 2023, a systematic review in The Lancet said that the protection afforded by infection was comparable to that from vaccination, albeit with an increased risk of severe illness and death from the disease of an initial infection.[230]

A January 2024 study by the CDC found that staying up to date on the vaccines could reduce the risk of strokes, blood clots and heart attacks related to COVID-19 in people aged 65 years or older or with a condition that makes them more vulnerable to said conditions.[231][232]

Duration of immunity

As of 2021, available evidence shows that fully vaccinated individuals and those previously infected with SARS-CoV-2 have a low risk of subsequent infection for at least six months.

immunocompromised, protection levels may be reduced after both vaccination and infection.[233] Available evidence indicates that the level of protection may not be the same for all variants of the virus.[233]

As of December 2021, there are no FDA-authorized or approved tests that providers or the public can use to determine if a person is protected from infection reliably.[233]

As of March 2022, elderly residents' protection against severe illness, hospitalization, and death in English care homes was high immediately after vaccination, but protection declined significantly in the months following vaccination.[236] Protection among care home staff, who were younger, declined much more slowly.[236] Regular boosters are recommended for older people, and boosters for care home residents every six months appear reasonable.[236]

The US Centers for Disease Control and Prevention (CDC) recommends a fourth dose of the Pfizer mRNA vaccine as of March 2022 for "certain immunocompromised individuals and people over the age of 50".[237][238]

Immune evasion by variants

In contrast to other investigated prior variants, the SARS-CoV-2 Omicron variant[239][240][241][242][243] and its BA.4/5 subvariants[244] have evaded immunity induced by vaccines, which may lead to breakthrough infections despite recent vaccination. Nevertheless, vaccines are thought to provide protection against severe illness, hospitalizations, and deaths due to Omicron.[245]

Vaccine adjustments

In June 2022,

bivalent vaccines to protect against the SARS-CoV-2 wild-type and the Omicron variant. The bivalent vaccines are well-tolerated and offer immunity to Omicron superior to previous mRNA vaccines.[246] In September 2022, the United States Food and Drug Administration (FDA) authorized the bivalent vaccines for use in the US.[247][248][249]

In June 2023, the FDA advised manufacturers that the 2023–2024 formulation of the COVID-19 vaccines for use in the US be updated to be a monovalent COVID-19 vaccine using the XBB.1.5 lineage of the Omicron variant.
[250][251]

Effectiveness against transmission

As of 2022, fully vaccinated individuals with breakthrough infections with the SARS-CoV-2 delta (B.1.617.2) variant have a peak viral load similar to unvaccinated cases and can transmit infection in household settings.[252]

Mix and match

According to studies, the combination of two different COVID‑19 vaccines, also called cross-vaccination or the mix-and-match method, provides protection equivalent to that of mRNA vaccines, including protection against the

Delta variant. Individuals who receive the combination of two different vaccines produce strong immune responses, with side effects no worse than those caused by standard regimens.[253][254]

Adverse events

For most people, the side effects, also called

All vaccines that are administered via

allergic to one or more ingredients in COVID‑19 vaccines. Typical side effects are stronger and more common in younger people and in subsequent doses, and up to 20% of people report a disruptive level of side effects after the second dose of an mRNA vaccine.[259] These side effects are less common or weaker in inactivated vaccines.[259] COVID‑19 vaccination-related enlargement of lymph nodes happens in 11.6% of those who received one dose of the vaccine and in 16% of those who received two doses.[260]

Experiments in mice show that intramuscular injections of lipid excipient nanoparticles (an inactive substance that serves as the vehicle or medium) cause particles to enter the blood plasma and many organs, with higher concentrations found in the liver and lower concentrations in the spleen, adrenal glands, and ovaries. The highest concentration of nanoparticles was found at the injection site itself.[261]

COVID‑19 vaccination is safe for breastfeeding people.[13] Temporary changes to the menstrual cycle in young women have been reported. However, these changes are "small compared with natural variation and quickly reverse."[262] In one study, women who received both doses of a two-dose vaccine during the same menstrual cycle (an atypical situation) may see their next period begin a couple of days late. They have about twice the usual risk of a clinically significant delay (about 10% of these women, compared to about 4% of unvaccinated women).[262] Cycle lengths return to normal after two menstrual cycles post-vaccination.[262] Women who received doses in separate cycles had approximately the same natural variation in cycle lengths as unvaccinated women.[262] Other temporary menstrual effects have been reported, such as heavier than normal menstrual bleeding after vaccination.[262]

Serious adverse events associated COVID‑19 vaccines are generally rare but of high interest to the public.[263] The official databases of reported adverse events include

Increased public awareness of these reporting systems and the extra reporting requirements under US FDA Emergency Use Authorization rules have increased reported adverse events.[265] Serious side effects are an ongoing area of study, and resources have been allocated to try and better understand them.[266][267][268] Research currently indicates that the rate and type of side effects are lower-risk than infection. For example, although vaccination may trigger some side effects, the effects experienced from an infection could be worse. Neurological side effects from getting COVID‑19 are hundreds of times more likely than from vaccination.[269]

Documented rare serious effects include:

  • allergic reaction.[270] Anaphylaxis affects one person per 250,000 to 400,000 doses administered.[259][271]
  • blood clots (thrombosis).[270] These vaccine-induced immune thrombocytopenia and thrombosis are associated with vaccines using an adenovirus system (Janssen and Oxford-AstraZeneca).[270] These affect about one person per 100,000.[259]
  • myocarditis and pericarditis, or inflammation of the heart.[270] There is a rare risk of myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the membrane covering the heart) after the mRNA COVID‑19 vaccines (Moderna or Pfizer-BioNTech). The risk of myocarditis after COVID‑19 vaccination is estimated to be 0.3 to 5 cases per 100,000 persons, with the highest risk in young males.[272] In an Israeli nation-wide population-based study (in which the Pfizer-BioNTech vaccine was exclusively given), the incidence rate of myocarditis was 54 cases out of 2.5 million vaccine recipients, with an overall incidence rate of 2 cases per 100,000 persons, with the highest incidence seen in young males (aged 16 to 29) at 10 cases per 100,000 vaccine recipients. Of the cases of myocarditis seen, 76% were mild in severity, with one case of cardiogenic shock (heart failure) and one death (in a person with a preexisting heart condition) reported within the 83-day follow-up period.[273] COVID‑19 vaccines may protect against myocarditis due to subsequent COVID‑19 infection.[274] The risk of myocarditis and pericarditis is significantly higher (up to 11 times higher with respect to myocarditis) after COVID‑19 infection as compared to COVID‑19 vaccination, with the possible exception of younger men (less than 40 years old) who may have a higher risk of myocarditis after the second Moderna mRNA vaccine (an additional 97 cases of myocarditis per 1 million persons vaccinated).[274]
  • thrombotic thrombocytopenia and other autoimmune diseases, which have been reported as adverse events after the COVID‑19 vaccine.[275]

There are rare reports of subjective hearing changes, including tinnitus, after vaccination.[271][276][277][278]

Society and culture

Distribution

Note about the table in this section: number and percentage of people who have received at least one dose of a COVID‑19 vaccine (unless noted otherwise). May include vaccination of non-citizens, which can push totals beyond 100% of the local population. The table is updated daily by a bot.[note 2]

Updated March 28, 2024.
COVID-19 vaccine distribution by country[279]
Location Vaccinated[b] Percent[c]
World[d][e] 5,630,420,091 70.60%
China China[f] 1,310,292,000 91.89%
India India 1,027,436,885 72.50%
European Union
European Union[g]
338,071,300 75.10%
United States
United States[h]
270,227,181 81.39%
Indonesia Indonesia 203,878,473 74.00%
Brazil Brazil 189,643,431 88.08%
Pakistan Pakistan 165,567,890 70.21%
Bangladesh Bangladesh 151,505,281 88.50%
Japan Japan 104,705,133 84.47%
Mexico Mexico 97,179,493 76.22%
Nigeria Nigeria 92,261,510 42.22%
Vietnam Vietnam 90,272,853 91.94%
Russia Russia 89,081,596 61.56%
Philippines
Philippines
78,484,848 67.92%
Iran Iran 65,199,831 73.63%
Germany Germany 64,876,299 77.82%
Turkey Turkey 57,941,051 67.89%
Thailand Thailand 57,005,497 79.62%
Egypt Egypt 56,907,319 51.27%
France France 54,677,678 80.63%
United Kingdom
United Kingdom
53,806,963 79.97%
Italy Italy[i] 50,936,719 86.28%
South Korea South Korea 44,784,499 86.43%
Ethiopia Ethiopia 44,073,766 35.72%
Colombia Colombia 43,012,174 82.92%
Argentina Argentina 41,529,058 91.25%
Spain Spain 41,351,234 86.95%
Myanmar Myanmar 34,777,314 64.64%
Canada Canada 34,763,194 90.40%
Tanzania Tanzania 34,434,933 52.57%
Peru Peru 30,563,708 89.76%
Malaysia Malaysia 28,138,094 82.91%
Nepal Nepal 27,883,196 91.28%
Saudi Arabia Saudi Arabia 27,041,364 74.27%
Morocco Morocco 25,020,168 66.80%
South Africa South Africa 24,209,938 40.42%
Poland Poland 22,877,472 57.40%
Mozambique Mozambique 22,869,646 69.37%
Australia Australia 22,236,698 84.95%
Venezuela Venezuela 22,157,232 78.29%
Taiwan Taiwan 21,899,240 91.65%
Uzbekistan Uzbekistan 21,674,823 62.59%
Uganda Uganda 19,488,104 41.25%
Afghanistan Afghanistan 18,896,999 45.95%
Chile Chile 18,088,517 92.27%
Sri Lanka Sri Lanka 17,143,761 78.53%
Angola Angola 16,522,932 46.43%
Ukraine Ukraine 15,729,617 36.19%
Democratic Republic of the Congo
Democratic Republic of the Congo
15,388,889 15.54%
Ecuador Ecuador 15,333,873 85.18%
Cambodia Cambodia 15,315,251 91.34%
Sudan Sudan 15,207,452 32.44%
Kenya Kenya 14,494,372 26.83%
Ivory Coast Ivory Coast 13,568,372 48.18%
Ghana Ghana 13,221,421 39.50%
Netherlands
Netherlands
12,596,446 71.72%
Zambia Zambia 11,637,730 58.14%
Iraq Iraq 11,332,925 25.47%
Kazakhstan Kazakhstan 10,858,101 55.98%
Cuba Cuba 10,800,127 96.32%
Rwanda Rwanda 10,572,981 76.75%
United Arab Emirates
United Arab Emirates
9,991,089 100.00%
Portugal Portugal 9,791,341 95.33%
Belgium Belgium 9,267,479 79.51%
Somalia Somalia 8,972,167 50.99%
Guatemala Guatemala 8,933,623 50.07%
Romania Romania 8,187,976 41.65%
Greece Greece 7,937,801 76.44%
Algeria Algeria 7,840,131 17.75%
Sweden Sweden 7,775,726 73.71%
Guinea Guinea 7,679,918 55.41%
Dominican Republic
Dominican Republic
7,367,193 65.61%
Bolivia Bolivia 7,361,008 60.94%
Tunisia Tunisia 7,218,871 58.42%
Czech Republic
Czech Republic
6,982,235 66.54%
Hong Kong Hong Kong 6,919,255 92.39%
Austria Austria 6,899,873 77.18%
Israel Israel 6,723,119 71.15%
Honduras Honduras 6,596,213 63.23%
Belarus Belarus 6,527,591 68.46%
Zimbabwe Zimbabwe 6,437,808 40.25%
Hungary Hungary 6,420,813 64.42%
Nicaragua Nicaragua 6,260,823 90.10%
Chad Chad 6,254,729 35.29%
Niger Niger 6,217,508 23.72%
Switzerland Switzerland 6,096,911 69.75%
Burkina Faso Burkina Faso 6,089,089 26.86%
Laos Laos 5,888,649 79.31%
Azerbaijan Azerbaijan 5,373,253 52.10%
Malawi Malawi 5,343,858 26.19%
Tajikistan Tajikistan 5,282,863 54.18%
Sierra Leone Sierra Leone 5,252,127 61.03%
Singapore Singapore 5,160,551 91.55%
Jordan Jordan 4,821,579 43.25%
Denmark Denmark 4,752,101 80.79%
El Salvador El Salvador 4,652,597 73.69%
Costa Rica Costa Rica 4,641,899 89.60%
Finland Finland 4,524,288 81.65%
Mali Mali 4,354,292 19.27%
Norway Norway 4,346,995 79.99%
New Zealand New Zealand 4,301,605 82.96%
South Sudan South Sudan 4,287,160 39.28%
Republic of Ireland
Republic of Ireland
4,111,392 81.85%
Paraguay Paraguay 3,993,938 58.90%
Liberia Liberia 3,825,381 72.14%
Cameroon Cameroon 3,753,733 13.45%
Benin Benin 3,697,190 27.69%
Panama Panama 3,533,477 80.15%
Kuwait Kuwait 3,457,498 80.99%
Serbia Serbia 3,354,075 48.81%
Syria Syria 3,295,630 14.90%
Oman Oman 3,257,365 71.18%
Uruguay Uruguay 3,010,451 87.95%
Qatar Qatar 2,852,178 105.83%
Slovakia Slovakia 2,822,919 51.82%
Lebanon Lebanon 2,740,227 49.92%
Madagascar Madagascar 2,700,391 9.12%
Senegal Senegal 2,684,696 15.50%
Central African Republic
Central African Republic
2,600,389 46.61%
Croatia Croatia 2,323,025 57.64%
Libya Libya 2,316,327 34.00%
Mongolia Mongolia 2,272,965 68.27%
Togo Togo 2,255,579 25.49%
Bulgaria Bulgaria 2,108,377 31.09%
Mauritania Mauritania 2,103,754 44.42%
State of Palestine
Palestine
2,012,767 38.34%
Lithuania Lithuania 1,958,254 71.21%
Botswana Botswana 1,951,054 74.18%
Kyrgyzstan Kyrgyzstan 1,736,541 26.19%
Georgia (country) Georgia 1,654,504 44.03%
Albania Albania 1,348,396 47.44%
Latvia Latvia 1,346,184 71.84%
Slovenia Slovenia 1,265,802 59.72%
Bahrain Bahrain 1,241,174 84.31%
Mauritius Mauritius 1,123,773 86.48%
Armenia Armenia 1,122,040 40.35%
Moldova Moldova 1,108,879 33.88%
Yemen Yemen 1,050,112 3.12%
Lesotho Lesotho 1,014,073 43.98%
Bosnia and Herzegovina Bosnia and Herzegovina 943,394 28.91%
The Gambia
Gambia
934,799 34.55%
Kosovo Kosovo 906,858 50.89%
East Timor
Timor-Leste
886,838 66.12%
Estonia Estonia 870,153 65.62%
Jamaica Jamaica 859,773 30.41%
North Macedonia North Macedonia 854,570 40.82%
Trinidad and Tobago Trinidad and Tobago 753,588 49.39%
Guinea-Bissau Guinea-Bissau 747,057 35.48%
Fiji Fiji 712,025 76.58%
Bhutan Bhutan 699,116 89.35%
Republic of the Congo
Republic of the Congo
695,760 11.92%
Macau Macau 679,703 97.77%
Cyprus Cyprus 670,969 74.88%
Namibia Namibia 629,767 24.53%
Eswatini Eswatini 526,050 43.78%
Haiti Haiti 521,396 4.50%
Guyana Guyana 495,285 61.24%
Luxembourg Luxembourg 481,957 74.42%
Malta Malta 478,953 89.81%
Brunei Brunei 451,149 100.48%
Comoros
Comoros
438,825 53.41%
Djibouti Djibouti 421,573 37.61%
Maldives Maldives 399,308 76.23%
Papua New Guinea Papua New Guinea 382,020 3.77%
Cape Verde
Cabo Verde
356,734 60.68%
Solomon Islands
Solomon Islands
343,821 47.47%
Gabon Gabon 311,040 13.02%
Iceland Iceland 309,770 84.00%
Northern Cyprus Northern Cyprus 301,673 78.80%
Montenegro Montenegro 292,783 46.63%
Equatorial Guinea Equatorial Guinea 270,109 16.53%
Suriname Suriname 267,820 45.26%
Belize Belize 258,473 63.78%
New Caledonia New Caledonia 192,375 66.35%
Samoa Samoa 191,403 86.07%
French Polynesia French Polynesia 190,908 62.33%
Vanuatu Vanuatu 176,624 54.06%
The Bahamas
Bahamas
174,810 42.64%
Barbados Barbados 163,846 58.17%
São Tomé and Príncipe
Sao Tome and Principe
140,256 61.68%
Curaçao Curaçao 108,601 56.81%
Kiribati Kiribati 100,900 76.88%
Aruba Aruba 90,546 85.05%
Seychelles Seychelles 88,520 82.62%
Tonga Tonga 87,342 81.73%
Jersey Jersey 84,365 76.14%
Isle of Man
Isle of Man
69,560 81.44%
Antigua and Barbuda Antigua and Barbuda 64,290 68.97%
Cayman Islands
Cayman Islands
62,023 90.25%
Saint Lucia Saint Lucia 60,140 33.43%
Andorra Andorra 57,901 72.52%
Guernsey Guernsey 54,223 85.62%
Bermuda Bermuda 48,554 75.65%
Grenada Grenada 44,241 35.26%
Gibraltar Gibraltar 42,175 129.07%
Faroe Islands
Faroe Islands
41,715 85.04%
Greenland Greenland 41,243 72.52%
Saint Vincent and the Grenadines Saint Vincent and the Grenadines 37,527 36.10%
Burundi Burundi 36,909 0.29%
Saint Kitts and Nevis Saint Kitts and Nevis 33,794 70.88%
Dominica Dominica 32,995 45.57%
Turks and Caicos Islands
Turks and Caicos Islands
32,815 71.76%
Turkmenistan Turkmenistan 32,240 0.53%
Sint Maarten Sint Maarten 29,788 67.41%
Liechtenstein Liechtenstein 26,771 68.02%
Monaco Monaco 26,672 67.49%
San Marino San Marino 26,357 77.50%
British Virgin Islands
British Virgin Islands
19,466 62.55%
Caribbean Netherlands
Caribbean Netherlands
19,109 72.26%
Cook Islands
Cook Islands
15,112 88.73%
Nauru Nauru 13,106 103.27%
Anguilla Anguilla 10,854 68.36%
Wallis and Futuna Wallis and Futuna 7,150 61.66%
Tuvalu Tuvalu 6,368 53.40%
Saint Helena, Ascension and Tristan da Cunha Saint Helena, Ascension and Tristan da Cunha 4,361 71.83%
Falkland Islands
Falkland Islands
2,632 75.57%
Tokelau Tokelau 2,203 116.38%
Montserrat Montserrat 2,104 47.68%
Niue Niue 1,650 102.23%
Pitcairn Islands
Pitcairn Islands
47 100.00%
North Korea North Korea 0 0.00%
  1. ^ The Oxford–AstraZeneca COVID‑19 vaccine is codenamed AZD1222,[171] and later supplied under brand names, including Vaxzevria[172] and Covishield.[173][174]
  2. ^ Number of people who have received at least one dose of a COVID-19 vaccine (unless noted otherwise).
  3. ^ Percentage of population that has received at least one dose of a COVID-19 vaccine. May include vaccination of non-citizens, which can push totals beyond 100% of the local population.
  4. ^ Countries which do not report data for a column are not included in that column's world total.
  5. ^ Vaccination note: Countries which do not report the number of people who have received at least one dose are not included in the world total.
  6. ^ Does not include special administrative regions (Hong Kong and Macau) or Taiwan.
  7. member states of the European Union
    are individually listed, but are also summed here for convenience. They are not double-counted in world totals.
  8. Freely Associated States
  9. ^ Vaccination note: Includes Vatican City

As of 3 January 2024, 13.53 billion COVID-19 vaccine doses have been administered worldwide, with 70.6 percent of the global population having received at least one dose.[280][281] While 4.19 million vaccines were then being administered daily, only 22.3 percent of people in low-income countries had received at least a first vaccine by September 2022, according to official reports from national health agencies, which are collated by Our World in Data.[282]

During a pandemic on the rapid timeline and scale of COVID-19 cases in 2020, international organizations like the World Health Organization (WHO) and Coalition for Epidemic Preparedness Innovations (CEPI), vaccine developers, governments, and industry evaluated the distribution of the eventual vaccine(s).[283] Individual countries producing a vaccine may be persuaded to favor the highest bidder for manufacturing or provide first-class service to their own country.[284][285][286] Experts emphasize that licensed vaccines should be available and affordable for people at the frontlines of healthcare and in most need.[284][286]

In April 2020, it was reported that the UK agreed to work with 20 other countries and global organizations, including France, Germany, and Italy, to find a vaccine and share the results, and that UK citizens would not get preferential access to any new COVID‑19 vaccines developed by taxpayer-funded UK universities.[287] Several companies planned to initially manufacture a vaccine at artificially low prices, then increase prices for profitability later if annual vaccinations are needed and as countries build stock for future needs.[286]

The WHO had set out the target to vaccinate 40% of the population of all countries by the end of 2021 and 70% by mid-2022,[288] but many countries missed the 40% target at the end of 2021.[289][290]

Access

Countries have extremely unequal access to the COVID‑19 vaccine. Vaccine equity has not been achieved or even approximated. The inequity has harmed both countries with poor access and countries with good access.[17][18][291]

Nations pledged to buy doses of the COVID‑19 vaccines before the doses were available. Though high-income nations represent only 14% of the global population, as of 15 November 2020, they had contracted to buy 51% of all pre-sold doses. Some high-income nations bought more doses than would be necessary to vaccinate their entire populations.[16]

Production of the Sputnik V vaccine in Brazil, January 2021

In January 2021, WHO Director-General Tedros Adhanom Ghebreyesus warned of problems with equitable distribution: "More than 39 million doses of vaccine have now been administered in at least 49 higher-income countries. Just 25 doses have been given in one lowest-income country. Not 25 million; not 25 thousand; just 25."[292]

Inside of a vaccination center in Brussels, Belgium, February 2021

In March 2021, it was revealed that the US attempted to convince Brazil not to purchase the

Sputnik V COVID‑19 vaccine, fearing "Russian influence" in Latin America.[293] Some nations involved in long-standing territorial disputes have reportedly had their access to vaccines blocked by competing nations; Palestine has accused Israel of blocking vaccine delivery to Gaza, while Taiwan has suggested that China has hampered its efforts to procure vaccine doses.[294][295][296]

A single dose of the COVID‑19 vaccines by AstraZeneca would cost 47 Egyptian pounds (EGP), and the authorities are selling them for between 100 and 200 EGP. A report by the Carnegie Endowment for International Peace cited the poverty rate in Egypt as around 29.7 percent, which constitutes approximately 30.5 million people, and claimed that about 15 million Egyptians would be unable to gain access to the luxury of vaccination. A human rights lawyer, Khaled Ali, launched a lawsuit against the government, forcing them to provide vaccinations free of charge to all members of the public.[297]

COVID‑19 vaccination for children aged 12–14 in Bhopal, India

According to immunologist Anthony Fauci, mutant strains of the virus and limited vaccine distribution pose continuing risks, and he said, "we have to get the entire world vaccinated, not just our own country."[298] Edward Bergmark and Arick Wierson are calling for a global vaccination effort and wrote that the wealthier nations' "me-first" mentality could ultimately backfire because the spread of the virus in poorer countries would lead to more variants, against which the vaccines could be less effective.[299]

In March 2021, the United States, Britain, European Union member states, and some other members of the World Trade Organization (WTO) blocked a push by more than eighty developing countries to waive COVID‑19 vaccine patent rights in an effort to boost production of vaccines for poor nations.[300] On 5 May 2021, the US government under President Joe Biden announced that it supports waiving intellectual property protections for COVID‑19 vaccines.[301] The Members of the European Parliament have backed a motion demanding the temporary lifting of intellectual property rights for COVID‑19 vaccines.[302]

An elderly man receiving a second dose of the CoronaVac vaccine in Brazil in April 2021

In a meeting in April 2021, the World Health Organization's emergency committee addressed concerns of persistent inequity in global vaccine distribution.[303] Although 9 percent of the world's population lives in the 29 poorest countries, these countries had received only 0.3% of all vaccines administered as of May 2021.[304] In March 2021, Brazilian journalism agency Agência Pública reported that the country vaccinated about twice as many people who declare themselves white than black and noted that mortality from COVID‑19 is higher in the black population.[305]

In May 2021,

Oxford–AstraZeneca COVID‑19 vaccine produced by the Serum Institute of India, which faced serious supply problems due to increased domestic vaccine needs in India from March to June 2021. Only a limited amount of vaccines can be distributed efficiently, and the shortfall of vaccines in South America and parts of Asia is due to a lack of expedient donations by richer nations. International aid organizations have pointed at Nepal, Sri Lanka, and the Maldives, as well as Argentina, Brazil, and some parts of the Caribbean, as problem areas where vaccines are in short supply. In mid-May 2021, UNICEF was also critical of the fact that most proposed donations of Moderna and Pfizer vaccines were not slated for delivery until the second half of 2021 or early in 2022.[306]

COVID‑19 mass vaccination queue in Finland, June 2021

In July 2021, the heads of the World Bank Group, the International Monetary Fund, the World Health Organization, and the World Trade Organization said in a joint statement: "As many countries are struggling with new variants and a third wave of COVID‑19 infections, accelerating access to vaccines becomes even more critical to ending the pandemic everywhere and achieving broad-based growth. We are deeply concerned about the limited vaccines, therapeutics, diagnostics, and support for deliveries available to developing countries."[307][308] In July 2021, The BMJ reported that countries had thrown out over 250,000 vaccine doses as supply exceeded demand and strict laws prevented the sharing of vaccines.[309] A survey by The New York Times found that over a million doses of vaccine had been thrown away in ten U.S. states because federal regulations prohibit recalling them, preventing their redistribution abroad.[310] Furthermore, doses donated close to expiration often cannot be administered quickly enough by recipient countries and end up having to be discarded.[311] To help overcome this problem, the Prime Minister of India, Narendra Modi, announced that they would make their digital vaccination management platform, CoWIN, open to the global community. He also announced that India would also release the source code for the contact tracing app Aarogya Setu for developers around the world. Around 142 countries, including Afghanistan, Bangladesh, Bhutan, the Maldives, Guyana, Antigua and Barbuda, St. Kitts and Nevis, and Zambia, expressed their interest in the application for COVID management.[312][313]

WTO Minister's meeting in November, which was expected to discuss the TRIPS IP waiver.[317][318][319]

A drive-through COVID‑19 vaccination center in Iran, August 2021

In August 2021, to reduce unequal distribution between rich and poor countries, the WHO called for a moratorium on booster doses at least until the end of September. However, in August, the United States government announced plans to offer booster doses eight months after the initial course to the general population, starting with priority groups. Before the announcement, the WHO harshly criticized this type of decision, citing the lack of evidence for the need for boosters, except for patients with specific conditions. At this time, vaccine coverage of at least one dose was 58% in high-income countries and only 1.3% in low-income countries, and 1.14 million Americans had already received an unauthorized booster dose. US officials argued that waning efficacy against mild and moderate disease might indicate reduced protection against severe disease in the coming months. Israel, France, Germany, and the United Kingdom have also started planning boosters for specific groups.[320][321][322] In September 2021, more than 140 former world leaders and Nobel laureates, including former President of France François Hollande, former Prime Minister of the United Kingdom Gordon Brown, former Prime Minister of New Zealand Helen Clark, and Professor Joseph Stiglitz, called on the candidates to be the next German chancellor to declare themselves in favor of waiving intellectual property rules for COVID‑19 vaccines and transferring vaccine technologies.[323] In November 2021, nursing unions in 28 countries filed a formal appeal with the United Nations over the refusal of the UK, EU, Norway, Switzerland, and Singapore to temporarily waive patents for COVID‑19 vaccines.[324]

During his first international trip, the President of Peru, Pedro Castillo, spoke at the seventy-sixth session of the United Nations General Assembly on 21 September 2021, proposing the creation of an international treaty signed by world leaders and pharmaceutical companies to guarantee universal vaccine access, arguing that "The battle against the pandemic has shown us the failure of the international community to cooperate under the principle of solidarity."[325][326]

Optimizing the societal benefit of vaccination may benefit from a strategy that is tailored to the state of the pandemic, the demographics of a country, the age of the recipients, the availability of vaccines, and the individual risk for severe disease.[10] In the UK, the interval between prime and booster doses was extended to vaccinate as many people as early as possible.[327] Many countries are starting to give an additional booster shot to the immunosuppressed[328][329] and the elderly,[330] and research predicts an additional benefit of personalizing vaccine doses in the setting of limited vaccine availability when a wave of virus Variants of Concern hits a country.[331]

Despite the extremely rapid development of effective

whole inactivated virus (WIV) and protein-based vaccines are also recommended. Organizations such as the Developing Countries Vaccine Manufacturers Network could help to support the production of such vaccines in developing countries, with lower production costs and greater ease of deployment.[17][333]

While vaccines substantially reduce the probability and severity of infection, it is still possible for fully vaccinated people to contract and spread COVID‑19.[334] Public health agencies have recommended that vaccinated people continue using preventive measures (wear face masks, social distance, wash hands) to avoid infecting others, especially vulnerable people, particularly in areas with high community spread. Governments have indicated that such recommendations will be reduced as vaccination rates increase and community spread declines.[335]

Economics

Moreover, an unequal distribution of vaccines will deepen inequality and exaggerate the gap between rich and poor and will reverse decades of hard-won progress on human development.
— United Nations, COVID vaccines: Widening inequality and millions vulnerable[336]

Vaccine inequity damages the global economy, disrupting the global

GDP and experience longer-term effects.[337] High-income countries would profit an estimated US$4.80 for every $1 spent on giving vaccines to lower-income countries.[291]

The International Monetary Fund sees the vaccine divide between rich and poor nations as a serious obstacle to a global economic recovery.[338] Vaccine inequity disproportionately affects refuge-providing states, as they tend to be poorer, and refugees and displaced people are economically more vulnerable even within those low-income states, so they have suffered more economically from vaccine inequity.[339][17]

Liability

Several governments agreed to shield pharmaceutical companies like Pfizer and Moderna from negligence claims related to COVID‑19 vaccines (and treatments), as in previous pandemics, when governments also took on liability for such claims.

In the US, these liability shields took effect on 4 February 2020, when the US Secretary of Health and Human Services,

money damages for any injuries that occur between 2020 and 2024 from the administration of vaccines and treatments related to COVID‑19.[340] The declaration is effective in the United States through 1 October 2024.[340]

In December 2020, the UK government granted Pfizer legal indemnity for its COVID‑19 vaccine.[341]

In the European Union, the COVID‑19 vaccines were granted a conditional marketing authorization, which does not exempt manufacturers from civil and administrative liability claims.[342] The EU conditional marketing authorizations were changed to standard authorizations in September 2022.[343] While the purchasing contracts with vaccine manufacturers remain secret, they do not contain liability exemptions, even for side effects not known at the time of licensure.[344]

The

pandemic parliamentary inquiry in Brazil, Pfizer's representative said that its terms for Brazil are the same as for all other countries with which it has signed deals.[346]

On 13 December 2022, the governor of Florida, Ron DeSantis, said that he would petition the state supreme court to convene a grand jury to investigate possible violations in respect to COVID‑19 vaccines,[347] and declared that his government would be able to get "the data whether they [the companies] want to give it or not".[348]

Controversy

In June 2021, a report revealed that the UB-612 vaccine, developed by the US-based Covaxx, was a for-profit venture initiated by Blackwater founder Erik Prince. In a series of text messages to Paul Behrends, the close associate recruited for the Covaxx project, Prince described the profit-making possibilities of selling the COVID‑19 vaccines. Covaxx provided no data from the clinical trials on safety or efficacy it conducted in Taiwan. The responsibility of creating distribution networks was assigned to an Abu Dhabi-based entity, which was mentioned as "Windward Capital" on the Covaxx letterhead but was actually Windward Holdings. The firm's sole shareholder, who handled "professional, scientific and technical activities", was Erik Prince. In March 2021, Covaxx raised $1.35 billion in a private placement.[349]

Misinformation and hesitancy


A protest against COVID-19 vaccination in London, United Kingdom

Anti-vaccination activists and other people in many countries have spread a variety of unfounded conspiracy theories and other misinformation about COVID-19 vaccines based on misunderstood or misrepresented science, religion, and law. These have included exaggerated claims about side effects, misrepresentations about how the immune system works and when and how COVID-19 vaccines are made, a story about COVID-19 being spread by 5G, and other false or distorted information. This misinformation has proliferated and may have made many people averse to vaccination.[350] This has led to governments and private organizations around the world introducing measures to incentivize or coerce vaccination, such as lotteries,[351] mandates,[352] and free entry to events,[353] which has in turn led to further misinformation about the legality and effect of these measures themselves.[354]

In the US, some prominent biomedical scientists who publicly advocate vaccination have been attacked and threatened in emails and on social media by anti-vaccination activists.
[355]

See also

  • COVID‑19 drug development
  • COVID‑19 drug repurposing research

Notes

  1. ^ Our World in Data (OWID) vaccination maps. Data is from public sources (Archived 21 December 2021 at the Wayback Machine). Data FAQ (Archived 10 March 2021 at the Wayback Machine).
  2. ^ The table data is automatically updated daily by a bot; see Template:COVID-19 data for more information. Scroll down past the table to find the documentation and the main reference. See also: Category:Automatically updated COVID-19 pandemic table templates.

References

  1. PMID 33341119
    .
  2. .
  3. ^ a b c d Rogers K (11 May 2022). "COVID-19 vaccine". Encyclopædia Britannica. Archived from the original on 12 June 2022. Retrieved 12 June 2022.
  4. ^ "Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland" (Press release). Swiss Agency for Therapeutic Products (Swissmedic). 18 December 2020. Archived from the original on 2 May 2021. Retrieved 5 July 2022.
  5. ^ "EMA recommends first COVID-19 vaccine for authorisation in the EU". European Medicines Agency (EMA) (Press release). 21 December 2020. Archived from the original on 30 January 2021. Retrieved 21 December 2020.
  6. S2CID 245262732
    .
  7. .
  8. ^ "COVID-19 vaccines saved nearly 20 million lives in a year, study says". CBS News. 24 June 2022. Archived from the original on 29 June 2022. Retrieved 27 June 2022.
  9. from the original on 18 January 2021. Retrieved 26 December 2020.
  10. ^ .
  11. ^
    hdl:10665/339218. WHO/2019-nCoV/vaccines/SAGE_recommendation/mRNA-1273/background/2021.1. Archived
    from the original on 13 June 2021. Retrieved 24 July 2021.
  12. ^ a b "Background document on the mRNA-1273 vaccine (Moderna) against COVID-19". World Health Organization (WHO). Archived from the original on 26 January 2022. Retrieved 23 January 2022.
  13. ^ a b "Pregnancy, breastfeeding, fertility and coronavirus (COVID-19) vaccination". NHS. 5 October 2022. Archived from the original on 15 October 2022. Retrieved 15 October 2022.
  14. ^ Richie H, Ortiz-Ospina E, Beltekian D, Methieu E, Hasell J, Macdonald B, et al. (March 2020). "Coronavirus (COVID-19) Vaccinations – Statistics and Research". Our World in Data. Archived from the original on 10 March 2021. Retrieved 7 February 2021.
  15. S2CID 227246811
    .
  16. ^ .
  17. ^ .
  18. ^ .
  19. ^ "The Nobel Prize in Physiology or Medicine 2023". NobelPrize.org. Archived from the original on 4 October 2023. Retrieved 3 October 2023.
  20. ^ "Hungarian and US scientists win Nobel for COVID-19 vaccine discoveries". Reuters. 2 October 2023. Archived from the original on 8 October 2023. Retrieved 3 October 2023.
  21. ^ "The Nobel Prize in Physiology or Medicine 2023". NobelPrize.org. Archived from the original on 4 February 2024. Retrieved 3 October 2023.
  22. ^ a b c Gates B (30 April 2020). "The vaccine race explained: What you need to know about the COVID-19 vaccine". The Gates Notes. Archived from the original on 14 May 2020. Retrieved 2 May 2020.
  23. PMID 14676007
    .
  24. .
  25. .
  26. .
  27. .
  28. .
  29. ^ .
  30. ^ "SARS (severe acute respiratory syndrome)". National Health Service. 5 March 2020. Archived from the original on 9 March 2020. Retrieved 31 January 2020.
  31. PMID 26791756
    .
  32. .
  33. .
  34. .
  35. ^ a b c Loftus P, Hopkins JS, Pancevski B (17 November 2020). "Moderna and Pfizer Are Reinventing Vaccines, Starting With Covid". The Wall Street Journal. Archived from the original on 6 November 2021. Retrieved 4 October 2021.
  36. PMID 33163000
    .
  37. .
  38. ^ Lewis T. "The New COVID Booster Shot Could Save Your Life; Get One Now, FDA Expert Says". Scientific American. Archived from the original on 7 November 2022. Retrieved 8 November 2022.
  39. PMID 34182569
    .
  40. ^ "Pfizer and Moderna Vaccines Likely to Produce Lasting Immunity, Study Finds". The New York Times. 28 June 2021. Archived from the original on 28 June 2021. Retrieved 23 January 2022.
  41. PMID 33123165
    .
  42. ^ .
  43. ^ from the original on 11 October 2020. Retrieved 10 March 2021.
  44. .
  45. ^ .
  46. .
  47. .
  48. .
  49. ^ .
  50. ^ .
  51. ^ Cross R (29 September 2020). "The tiny tweak behind COVID-19 vaccines". Chemical & Engineering News. Vol. 98, no. 38. Archived from the original on 16 February 2021. Retrieved 15 April 2021.
  52. S2CID 221887746
    .
  53. .
  54. .
  55. from the original on 9 October 2021. Retrieved 17 January 2021.
  56. ^ "COVID-19 ACIP Vaccine Recommendations". U.S. Centers for Disease Control and Prevention (CDC). Archived from the original on 3 November 2021. Retrieved 18 February 2021.
  57. ^ "Safe COVID-19 vaccines for Europeans". European Commission. Archived from the original on 4 November 2021. Retrieved 19 February 2021.
  58. ^ "Regulatory Decision Summary – Pfizer–BioNTech COVID-19 Vaccine". Health Canada, Government of Canada. 9 December 2020. Archived from the original on 30 January 2021. Retrieved 9 December 2020.
  59. ^ "Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults". ClinicalTrials.gov. 30 April 2020. NCT04368728. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  60. ^ "A Multi-site Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults". EU Clinical Trials Register. 14 April 2020. EudraCT 2020-001038-36. Archived from the original on 22 April 2020. Retrieved 22 April 2020.
  61. ^ "A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19". ClinicalTrials.gov. 14 July 2020. NCT04470427. Archived from the original on 11 October 2020. Retrieved 27 July 2020.
  62. ^ Palca J (27 July 2020). "COVID-19 vaccine candidate heads to widespread testing in U.S." NPR. Archived from the original on 11 October 2020. Retrieved 27 July 2020.
  63. ^ "CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60". CureVac (Press release). 30 June 2021. Archived from the original on 12 October 2021. Retrieved 2 July 2021.
  64. ^
    PMID 33571463
    .
  65. ^ a b "What are viral vector-based vaccines and how could they be used against COVID-19?". Gavi, the Vaccine Alliance (GAVI). 2020. Archived from the original on 11 November 2021. Retrieved 26 January 2021.
  66. ^ "Understanding Viral Vector COVID-19 Vaccines". U.S. Centers for Disease Control and Prevention (CDC). 13 April 2021. Archived from the original on 13 November 2021. Retrieved 19 April 2021.
  67. ^ "Investigating a Vaccine Against COVID-19". ClinicalTrials.gov. 26 May 2020. NCT04400838. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  68. ^ "A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19". EU Clinical Trials Register. 21 April 2020. EudraCT 2020-001228-32. Archived from the original on 5 October 2020. Retrieved 3 August 2020.
  69. .
  70. ^ Corum J, Carl Z (8 January 2021). "How Gamaleya's Vaccine Works". The New York Times. Archived from the original on 20 April 2021. Retrieved 27 January 2021.
  71. ^ "A Study of Ad26.COV2.S in Adults". 4 August 2020. Archived from the original on 16 September 2020. Retrieved 23 August 2020.
  72. ^ "A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants". US National Library of Medicine. Archived from the original on 26 September 2020.
  73. ^ Johnson C, McGinley L. "Johnson & Johnson seeks emergency FDA authorization for single-shot coronavirus vaccine". The Washington Post. Archived from the original on 5 February 2021. Retrieved 10 February 2021.
  74. ^ "It's not just Johnson & Johnson: China has a single-dose COVID-19 vaccine that's 65% effective". Fortune. Archived from the original on 8 August 2021. Retrieved 28 February 2021.
  75. PMID 32796842
    .
  76. ^ "Single dose vaccine, Sputnik Light, authorized for use in Russia". Sputnik V (Press release). Archived from the original on 14 November 2021. Retrieved 12 August 2021.
  77. .
  78. .
  79. ^ "Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19) (Renqiu)". ClinicalTrials.gov. 12 May 2020. NCT04383574. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  80. ^ "Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV)". ClinicalTrials.gov. 2 July 2020. NCT04456595. Archived from the original on 11 October 2020. Retrieved 3 August 2020.
  81. ^ PT. Bio Farma (August 2020). "A Phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-COV-2 inactivated vaccine in healthy adults aged 18–59 years in Indonesia". Registri Penyakit Indonesia. Archived from the original on 11 October 2020. Retrieved 15 August 2020.
  82. ^ Chen W, Al Kaabi N (July 2020). "A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)". Chinese Clinical Trial Registry. Archived from the original on 11 October 2020. Retrieved 15 August 2020.
  83. ^ Ivanova P (20 February 2021). "Russia approves its third COVID-19 vaccine, CoviVac". Reuters. Archived from the original on 28 February 2021. Retrieved 11 April 2021.
  84. ^ "Kazakhstan rolls out its own COVID-19 vaccine". Reuters. 27 April 2021. Archived from the original on 4 November 2021. Retrieved 2 July 2021.
  85. ^ "FarsNews Agency Iran Licenses Emergency Injection of Home-Made Anti-Coronavirus Vaccine". Fars News Agency. 14 June 2021. Archived from the original on 9 October 2021. Retrieved 25 August 2021.
  86. ^ "VLA2001 COVID-19 Vaccine". Precision Vaccinations. 31 December 2020. Archived from the original on 13 January 2021. Retrieved 11 January 2021.
  87. ^ "Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactivated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults". U.S. National Library of Medicine. 30 December 2020. Archived from the original on 14 February 2021. Retrieved 11 January 2021.
  88. ^ "Module 2 – Subunit vaccines". WHO Vaccine Safety Basics. Archived from the original on 8 August 2021. Retrieved 17 January 2021.
  89. ^ "Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19 (EpiVacCorona)". ClinicalTrials.gov. 22 September 2020. NCT04368988. Archived from the original on 29 June 2021. Retrieved 16 November 2020.
  90. ^ "MVC COVID-19 Vaccine Obtains Taiwan EUA Approval". Medigen Vaccine Biologics. Archived from the original on 27 November 2021. Retrieved 7 August 2021.
  91. ^ Achom D (28 December 2021). "India Clears 2 New Vaccines And Merck's Covid Pill: 10 Points". NDTV.com. Archived from the original on 28 December 2021. Retrieved 19 January 2022.
  92. ^ Bottazzi ME, Hotez PJ (30 December 2021). "A COVID Vaccine for All". Scientific American. Archived from the original on 30 December 2021. Retrieved 19 January 2022.
  93. ^ "VidPrevtyn Beta". European Medicines Agency (EMA). 4 November 2022. Archived from the original on 11 November 2022. Retrieved 12 November 2022. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  94. ^ "EMA recommends approval of VidPrevtyn Beta as a COVID-19 booster vaccine". European Medicines Agency (EMA) (Press release). 10 November 2022. Archived from the original on 12 November 2022. Retrieved 12 November 2022. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  95. ^ "Iran-Cuba vaccine enters phase three clinical trials". Tehran Times. 26 April 2021. Archived from the original on 19 July 2021. Retrieved 7 September 2021.
  96. ^ Barrie R (31 March 2023). "Hipra's Covid-19 booster gets EMA nod and enters an uncertain landscape". Pharmaceutical Technology. Archived from the original on 10 April 2023. Retrieved 9 April 2023.
  97. ^ "Bimervax EPAR". European Medicines Agency. 5 April 2023. Archived from the original on 8 April 2023. Retrieved 9 April 2023.
  98. ^ "A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults". ClinicalTrials.gov. 3 August 2020. NCT04495933. Archived from the original on 11 October 2020. Retrieved 4 August 2020.
  99. ^ "Australian vaccine trials stopped due to HIV false positives". Deutsche Welle. 11 December 2020. Archived from the original on 26 January 2021. Retrieved 9 January 2023.
  100. ^ "Covid: Australian vaccine abandoned over false HIV response". BBC News Online. 11 December 2020. Archived from the original on 16 January 2021. Retrieved 9 April 2023.
  101. ^ "Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant". ClinicalTrials.gov. 30 April 2020. NCT04368988. Archived from the original on 14 July 2020. Retrieved 14 July 2020.
  102. ^ "A prospective, randomized, adaptive, phase I/II clinical study to evaluate the safety and immunogenicity of Novel Corona Virus −2019-nCov vaccine candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects". India: Clinical Trials Registry. 15 December 2020. CTRI/2020/07/026352. Archived from the original on 22 November 2020.
  103. ^ "Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers". ClinicalTrials.gov. 7 April 2020. NCT04336410. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  104. ^ "IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO's COVID‑19 DNA vaccine in South Korea". International Vaccine Institute. 16 April 2020. Archived from the original on 24 September 2020. Retrieved 23 April 2020.
  105. ^ "Study of COVID-19 DNA Vaccine (AG0301-COVID19)". ClinicalTrials.gov. 9 July 2020. NCT04463472. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  106. ^ "Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults". ClinicalTrials.gov. 24 June 2020. NCT04445389. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  107. ^ "S. Korea's Genexine begins human trial of coronavirus vaccine". Reuters. 19 June 2020. Archived from the original on 11 October 2020. Retrieved 25 June 2020.
  108. ^ Chang LJ (March 2020). "Safety and Immunity of Covid-19 aAPC Vaccine". ClinicalTrials.gov. NCT04299724. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  109. ^ "Immunity and Safety of Covid-19 Synthetic Minigene Vaccine". ClinicalTrials.gov. February 2020. NCT04276896. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  110. ^ "A Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults". ClinicalTrials.gov. November 2020. NCT04608305. Archived from the original on 3 May 2021. Retrieved 2 January 2021.
  111. from the original on 11 June 2020. Retrieved 31 December 2020.
  112. ^ "Bacille Calmette-Guérin (BCG) vaccination and COVID-19". World Health Organization (WHO). 12 April 2020. Archived from the original on 30 April 2020. Retrieved 1 May 2020.
  113. ^ "Urgent global health needs addressed by Novavax". Novavax. Archived from the original on 12 May 2021. Retrieved 30 January 2021.
  114. ^
    PMID 32931361
    .
  115. ^ .
  116. ^ "Live Attenuated Influenza Vaccine [LAIV] (The Nasal Spray Flu Vaccine)". U.S. Centers for Disease Control and Prevention (CDC). 3 August 2021. Archived from the original on 14 October 2019. Retrieved 8 September 2021.
  117. ^ Moritsugu K (26 October 2022). "Afraid of needles? China using inhalable COVID-19 vaccine". AP News. Archived from the original on 1 November 2022. Retrieved 2 November 2022.
  118. ^ Lovelace Jr B (19 July 2022). "Nasal vaccines may stop Covid infections. Will we get them soon?". NBC News. Archived from the original on 19 July 2022. Retrieved 19 July 2022.
  119. ^ "Two inhaled covid vaccines have been approved—but we don't know yet how good they are". MIT Technology Review. Archived from the original on 21 October 2022. Retrieved 21 October 2022.
  120. ^
    S2CID 252121594
    .
  121. .
  122. ^ .
  123. ^ "Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection". ClinicalTrials.gov. 30 December 2020. Archived from the original on 13 May 2022. Retrieved 5 September 2022.
  124. ^ "Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19". ClinicalTrials.gov. 16 August 2021. Archived from the original on 18 June 2022. Retrieved 5 September 2022.
  125. ^ Mullin E (9 June 2021). "A 'Universal' Coronavirus Vaccine to Prevent the Next Pandemic". Scientific American. Archived from the original on 20 December 2021. Retrieved 20 December 2021.
  126. ^ Joi P (13 July 2021). "Could a universal coronavirus vaccine soon be a reality?". GAVI. Archived from the original on 20 December 2021. Retrieved 20 December 2021.
  127. ^ Bush E (15 December 2021). "Fauci pushes for universal coronavirus vaccine". NBC News. Archived from the original on 20 December 2021. Retrieved 20 December 2021.
  128. ^ "National COVID-19 Preparedness Plan" (PDF). The White House. March 2022. pp. 9, 21, 29. Archived from the original (PDF) on 26 March 2022. Retrieved 29 March 2022.
  129. ^ "Phase 1 Clinical Trial of WRAIR-developed COVID-19 Vaccine Begins". 5 April 2022. Archived from the original on 11 July 2022. Retrieved 11 July 2022.
  130. ^ Haridy R (7 July 2022). "Another universal coronavirus vaccine readies for human trials". New Atlas. Archived from the original on 11 July 2022. Retrieved 11 July 2022.
  131. ^
    PMID 29232151
    .
  132. ^ .
  133. .
  134. .
  135. ^ from the original on 11 May 2020. Retrieved 2 May 2020.
  136. ^ a b c d Steenhuysen J, Eisler P, Martell A, Nebehay S (27 April 2020). "Special Report: Countries, companies risk billions in race for coronavirus vaccine". Reuters. Archived from the original on 15 May 2020. Retrieved 2 May 2020.
  137. ^ Jeong-ho L, Zheng W, Zhou L (26 January 2020). "Chinese scientists race to develop vaccine as coronavirus death toll jumps". South China Morning Post. Archived from the original on 26 January 2020. Retrieved 28 January 2020.
  138. from the original on 4 May 2020. Retrieved 4 May 2020.
  139. .
  140. ^ Blackwell T (20 April 2020). "COVID-19 vaccine researchers say pandemic lockdown placing many serious obstacles to their work". National Post. Archived from the original on 24 April 2020. Retrieved 3 May 2020.
  141. ^ Chen J (4 May 2020). "Covid-19 has shuttered labs. It could put a generation of researchers at risk". Stat. Archived from the original on 6 May 2020. Retrieved 4 May 2020.
  142. ^ "Vaccine Safety – Vaccines". US Department of Health and Human Services. Archived from the original on 22 April 2020. Retrieved 13 April 2020.
  143. ^ "The drug development process". U.S. Food and Drug Administration (FDA). 4 January 2018. Archived from the original on 22 February 2020. Retrieved 12 April 2020.
  144. S2CID 219911109
    .
  145. .
  146. ^ Howard J, Stracqualursi V (18 June 2020). "Fauci warns of 'anti-science bias' being a problem in US". CNN. Archived from the original on 21 June 2020. Retrieved 21 June 2020.
  147. ^ "Vaccines: The Emergency Authorisation Procedure". European Medicines Agency (EMA). 2020. Archived from the original on 24 September 2020. Retrieved 21 August 2020.
  148. ^ Byrne J (19 October 2020). "Moderna COVID-19 vaccine under rolling review process in Canada, EU". BioPharma-Reporter.com, William Reed Business Media Ltd. Archived from the original on 25 February 2021. Retrieved 25 November 2020.
  149. ^ Dangerfield K (20 November 2020). "Pfizer files for emergency use of coronavirus vaccine in U.S. – what about in Canada?". Global News. Archived from the original on 25 January 2021. Retrieved 25 November 2020.
  150. ^ "G20 launches initiative for health tools needed to combat the coronavirus". The Globe and Mail. 25 April 2020. Archived from the original on 27 April 2020. Retrieved 1 February 2021.
  151. ^ "Access to COVID-19 Tools (ACT) Accelerator" (PDF). World Health Organization (WHO). 24 April 2020. Archived (PDF) from the original on 25 April 2020. Retrieved 1 February 2021.
  152. ^ "The ACT-Accelerator: frequently asked questions (FAQ)". World Health Organization (WHO). 2020. Archived from the original on 4 May 2021. Retrieved 16 December 2020.
  153. ^ "Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine". World Health Organization (WHO). 27 April 2020. Archived from the original on 30 April 2020. Retrieved 2 May 2020. It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. [The] WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months, and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale.
  154. ^ Abedi M (23 March 2020). "Canada to spend $192M on developing COVID-19 vaccine". Global News. Archived from the original on 9 April 2020. Retrieved 24 March 2020.
  155. ^ "Government of Canada's research response to COVID-19". Government of Canada. 23 April 2020. Archived from the original on 13 May 2020. Retrieved 4 May 2020.
  156. ^ Takada N, Satake M (2 May 2020). "US and China unleash wallets in race for coronavirus vaccine". Nikkei Asian Review. Archived from the original on 10 May 2020. Retrieved 3 May 2020.
  157. ^ Morriss E (22 April 2020). "Government launches coronavirus vaccine taskforce as human clinical trials start". Pharmafield. Archived from the original on 26 June 2020. Retrieved 3 May 2020.
  158. ^ Kuznia R, Polglase K, Mezzofiore G (1 May 2020). "In quest for vaccine, US makes 'big bet' on company with unproven technology". CNN. Archived from the original on 13 May 2020. Retrieved 2 May 2020.
  159. PMID 32409451
    .
  160. ^ Sink J, Fabian J, Griffin R (15 May 2020). "Trump introduces 'Warp Speed' leaders to hasten COVID-19 vaccine". Bloomberg. Archived from the original on 21 May 2020. Retrieved 15 May 2020.
  161. ^ LaHucik K (17 June 2021). "U.S. injects $3B-plus into COVID-19 research to develop antiviral pill within a year". Fierce Biotech. Archived from the original on 9 October 2021. Retrieved 11 July 2021.
  162. ^
    London School of Hygiene & Tropical Medicine
    . 12 July 2021. Retrieved 10 March 2021.
  163. ^ "Approved Vaccines". COVID 19 Vaccine Tracker, McGill University. 12 July 2021.
  164. PMID 33835769
    .
  165. .
  166. .
  167. ^ . Although initially several terms were used to describe the syndrome … the term that has gained widespread use is vaccine-induced immune thrombotic thrombocytopenia (VITT). Thrombosis with thrombocytopenia syndrome has also been used, but it is a more general term that can be caused by other conditions
  168. ^ . We believe the name "VITT" works well … the term clearly denotes the key features of the disorder … provides a useful mnemonic for disease recognition in the usual sequence of events … need not mandate that thrombosis be present … "TTS" … has limited clinical utility, since many conditions … present with the duad of thrombosis and thrombocytopenia
  169. ^ a b "Use of AstraZeneca COVID-19 vaccine in younger adults" (Press release). Health Canada. 29 March 2021. Archived from the original on 11 October 2021. Retrieved 2 April 2021.
  170. PMID 34062319
    .
  171. ^ "AstraZeneca COVID-19 Vaccine (AZD1222)" (PDF). ACIP COVID-19 Emergency Meeting. AstraZeneca. 27 January 2021. Archived (PDF) from the original on 27 January 2021. Retrieved 16 April 2021.
  172. ^ "Vaxzevria (previously COVID-19 Vaccine AstraZeneca) EPAR". European Medicines Agency (EMA). 25 January 2021. Archived from the original on 21 April 2021. Retrieved 16 April 2021. The name of the vaccine was changed to Vaxzevria on 25 March 2021. Vaxzevria (COVID‑19 Vaccine (ChAdOx1-S recombinant) EMA/182334/2021 Archived 15 April 2021 at the Wayback Machine Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  173. ^ "ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant) - Covishield". Serum Institute Of India. Archived from the original on 19 April 2021. Retrieved 16 April 2021.
  174. ^ "AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine". World Health Organization (WHO). Archived from the original on 28 November 2021. Retrieved 28 November 2021.
  175. ^ a b "COVID-19 vaccine safety update: Vaxzevria" (PDF). European Medicines Agency (EMA). 28 March 2021. Archived (PDF) from the original on 13 April 2021. Retrieved 31 March 2021.
  176. ^ Marks P. "Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine". Archived from the original on 20 May 2021. Retrieved 13 April 2021.
  177. ^ "Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals". U.S. Food and Drug Administration. 5 May 2022. Archived from the original on 7 May 2022. Retrieved 7 May 2022.
  178. ^ Medical Director of AstraZeneca AB (13 April 2021). "Direct healthcare professional communication (DHPC): Vaxzevria (previously COVID-19 Vaccine AstraZeneca): link between the vaccine and the occurrence of thrombosis in combination with thrombocytopenia" (PDF). European Medicines Agency (EMA). Archived (PDF) from the original on 18 July 2022. Retrieved 13 April 2021.
  179. ^ "Research and analysis — Coronavirus vaccine - weekly summary of Yellow Card reporting". Medicines and Healthcare products Regulatory Agency (MHRA). 1 April 2021. Archived from the original on 20 May 2021. Retrieved 3 April 2020.
  180. ^ EMA (7 April 2021). EMA press conference 7th April — Conclusion of the assessment of the Pharmacovigilance Risk Assessment Committee (PRAC) of COVID-19 Vaccine AstraZeneca and thromboembolic events. European Medicines Agency (EMA). Retrieved 7 April 2021 – via Youtube.
  181. ^ "World Health Organization timeline – COVID-19". World Health Organization (WHO). 27 April 2020. Archived from the original on 29 April 2020. Retrieved 2 May 2020.
  182. ^
    PMID 32273591
    .
  183. ^ .
  184. .
  185. ^ .
  186. from the original on 9 June 2020. Retrieved 9 June 2020.
  187. ^ "COVID-19 pandemic reveals the risks of relying on private sector for life-saving vaccines, says expert". CBC Radio. 8 May 2020. Archived from the original on 13 May 2020. Retrieved 8 June 2020.
  188. ^ Ahmed DD (4 June 2020). "Oxford, AstraZeneca COVID-19 deal reinforces 'vaccine sovereignty'". Stat. Archived from the original on 12 June 2020. Retrieved 8 June 2020.
  189. ^ Grenfell R, Drew T (14 February 2020). "Here's why the WHO says a coronavirus vaccine is 18 months away". Business Insider. Archived from the original on 5 December 2020. Retrieved 11 November 2020.
  190. ^ Offit P. "TWiV 720: With vaccines, Offit is on it". This Week in Virology Podcast. Vincent Racaniello Youtube Channel. Archived from the original on 25 May 2021. Retrieved 14 July 2021.
  191. ^ "Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine". World Health Organization (WHO). 27 April 2020. Archived from the original on 30 April 2020. Retrieved 2 May 2020. It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. [The] WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale.
  192. PMID 32243778
    . CEPI estimates that developing up to three vaccines in the next 12–18 months will require an investment of at least US$2 billion. This estimate includes Phase 1 clinical trials of eight vaccine candidates, progression of up to six candidates through Phase 2 and 3 trials, completion of regulatory and quality requirements for at least three vaccines, and enhancing global manufacturing capacity for three vaccines.
  193. ^ "WHO 'backed China's emergency use' of experimental Covid-19 vaccines". South China Morning Post. 25 September 2020. Archived from the original on 26 September 2020. Retrieved 26 September 2020.
  194. from the original on 27 September 2020. Retrieved 28 September 2020.
  195. ^ "Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine". Pfizer (Press release). 20 November 2020. Archived from the original on 29 January 2021. Retrieved 20 November 2020.
  196. ^ Park A (20 November 2020). "Exclusive: Pfizer CEO Discusses Submitting the First COVID-19 Vaccine Clearance Request to the FDA". Time. Archived from the original on 29 January 2021. Retrieved 20 November 2020.
  197. ^ "Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine". Medicines & Healthcare products Regulatory Agency (MHRA). 8 December 2020. Archived from the original on 15 March 2021. Retrieved 13 December 2020.
  198. ^ "Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine". Medicines and Healthcare products Regulatory Agency (MHRA). 3 December 2020. Archived from the original on 26 February 2021. Retrieved 19 December 2020.
  199. ^ "UK medicines regulator gives approval for first UK COVID-19 vaccine". Medicines and Healthcare Products Regulatory Agency, Government of the UK. 2 December 2020. Archived from the original on 17 March 2021. Retrieved 2 December 2020.
  200. ^ Mueller B (2 December 2020). "U.K. Approves Pfizer Coronavirus Vaccine, a First in the West". The New York Times. Archived from the original on 28 January 2021. Retrieved 2 December 2020.
  201. ^ Roberts M (2 December 2020). "Covid Pfizer vaccine approved for use next week in UK". BBC News Online. Archived from the original on 2 December 2020. Retrieved 2 December 2020.
  202. ^ "Questions and Answers: COVID-19 vaccination in the EU". European Commission. 21 December 2020. Archived from the original on 29 January 2021. Retrieved 21 December 2020.
  203. ^ "Bahrain second in the world to approve the Pfizer/BioNTech Covid-19 vaccine". Bahrain News Agency. 4 December 2020. Archived from the original on 17 December 2020. Retrieved 9 December 2020.
  204. ^ "UAE: Ministry of Health announces 86 per cent vaccine efficacy". Gulf News. Archived from the original on 24 December 2020. Retrieved 9 December 2020.
  205. ^ Thomas K, LaFraniere S, Weiland N, Goodnough A, Haberman M (12 December 2020). "F.D.A. Clears Pfizer Vaccine, and Millions of Doses Will Be Shipped Right Away". The New York Times. Archived from the original on 12 December 2020. Retrieved 12 December 2020.
  206. ^ "FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine". U.S. Food and Drug Administration (FDA) (Press release). Archived from the original on 17 March 2021. Retrieved 18 December 2020.
  207. (PDF) from the original on 9 February 2021. Retrieved 18 January 2021.
  208. ^ Lovelace Jr B (19 December 2020). "FDA approves second Covid vaccine for emergency use as it clears Moderna's for U.S. distribution". CNBC. Archived from the original on 26 January 2021. Retrieved 19 December 2020.
  209. ^ Corum J, Zimmer C (17 December 2020). "How the Oxford-AstraZeneca Vaccine Works". The New York Times. Archived from the original on 5 January 2022. Retrieved 2 May 2021.
  210. ^ Tétrault-Farber M, Vasilyeva G (31 March 2021). "Russia registers world's first COVID-19 vaccine for animals". Reuters. Archived from the original on 17 December 2021. Retrieved 4 April 2021.
  211. ^ "В России зарегистрировали первую в мире вакцину против COVID-19 для животных" [The world's first COVID-19 vaccine for animals was registered in Russia]. TASS (in Russian). Moscow. 31 March 2021. Archived from the original on 19 May 2021. Retrieved 19 May 2021.
  212. ^ MORITSUGU K (26 October 2022). "Afraid of needles? China using inhalable COVID-19 vaccine". AP NEWS. Retrieved 2 November 2022.
  213. S2CID 238747462
    .
  214. .
  215. ^ Taylor R (2 November 2021). "Sequences of Covid-19 vaccines released via WhatDoTheyKnow". mySociety. Archived from the original on 5 November 2021. Retrieved 2 November 2021.
  216. ^ "Data on COVID-19 mortality by vaccination status". Our World in Data (CDC data). April 2023. Archived from the original on 16 October 2023. Data source: Centers for Disease Control and Prevention, Vaccine Breakthrough/Surveillance and Analytics Team.
  217. PMID 36868258
    .
  218. ^ Holcombe M, Waldrop T (11 September 2021). "CDC study: Unvaccinated 11 times more likely to die from Covid-19". CNN. Retrieved 11 September 2021.
  219. PMID 34529637
    .
  220. .
  221. from the original on 28 August 2021. Retrieved 28 October 2021.
  222. ^ "Among the unvaccinated, Delta variant more than doubles risk of hospitalization" Archived 8 November 2021 at the Wayback Machine, Los Angeles Times, 28 August 2021
  223. ^ "WHO/ECDC: Nearly half a million lives saved by COVID-19 vaccination in less than a year". 25 November 2021.
  224. ^ "Coronavirus (COVID-19) booster vaccine". NHS. Government Digital Service. 17 September 2021. Retrieved 11 December 2021.
  225. ^ SARS-CoV-2 variants of concern and variants under investigation in England, technical briefing 31 (PDF) (Briefing). Public Health England. 10 December 2021. pp. 3–5, 20–22. GOV-10645. Archived (PDF) from the original on 18 December 2021. Retrieved 10 December 2021.
  226. ^ Gore D (9 February 2022). "Latest CDC Data: Unvaccinated Adults 97 Times More Likely to Die from COVID-19 Than Boosted Adults". FactCheck.org. Retrieved 11 February 2022.
  227. PMID 35236664
    .
  228. .
  229. .
  230. from the original on 14 January 2024. Retrieved 14 January 2024.
  231. ^ Mole B (12 January 2024). "COVID shots protect against COVID-related strokes, heart attacks, study finds". Ars Technica. Archived from the original on 14 January 2024. Retrieved 14 January 2024.
  232. ^ a b c d e f "Science Brief: SARS-CoV-2 Infection-induced and Vaccine-induced Immunity". Centers for Disease Control and Prevention (CDC). 29 October 2021. Archived from the original on 4 December 2021. Retrieved 4 December 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  233. PMID 34614326
    .
  234. ^ "COVID-19 Booster Shot". Centers for Disease Control and Prevention. 29 November 2021. Archived from the original on 21 August 2021. Retrieved 4 December 2021.
  235. ^ a b c Devlin H (18 March 2022). "Covid immunity declines steeply in care home residents in England – study". The Guardian. Archived from the original on 23 March 2022. Retrieved 12 May 2022.
  236. ^ Kimball S. "CDC recommends fourth Pfizer and Moderna Covid vaccine doses for people age 50 and older". CNBC. Archived from the original on 3 September 2022. Retrieved 22 August 2022.
  237. ^ "Coronavirus Disease 2019". Centers for Disease Control and Prevention (Press release). 29 March 2022. Archived from the original on 1 September 2022. Retrieved 22 August 2022.
  238. (PDF) from the original on 18 December 2021. Retrieved 27 January 2022.
  239. ^ "Study findings suggest spread of Omicron can be ascribed to immune evasiveness rather than an increase in transmissibility". News-Medical.net. 5 January 2022. Archived from the original on 21 January 2022. Retrieved 17 January 2022.
  240. S2CID 245455422
    .
  241. .
  242. .
  243. ^ "How soon after catching COVID-19 can you get it again?". ABC News. 2 May 2022. Archived from the original on 9 July 2022. Retrieved 24 June 2022.
  244. ^ "Omicron Variant: What You Need to Know". Centers for Disease Control and Prevention. 20 December 2021. Archived from the original on 27 January 2022. Retrieved 27 January 2022.
  245. PMID 36303305
    .
  246. ^ "COVID-19 Vaccine Boosters". U.S. Food and Drug Administration (FDA). 27 September 2022. Archived from the original on 8 October 2022. Retrieved 8 October 2022.
  247. ^ "Moderna COVID-19 Vaccines". U.S. Food and Drug Administration. 7 October 2022. Archived from the original on 7 October 2022. Retrieved 8 October 2022.
  248. ^ "Pfizer-BioNTech COVID-19 Vaccines". U.S. Food and Drug Administration. 3 October 2022. Archived from the original on 8 October 2022. Retrieved 8 October 2022.
  249. ^ "Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2023". U.S. Food and Drug Administration (FDA). 15 June 2023. Retrieved 16 June 2023. Public Domain This article incorporates text from this source, which is in the public domain.
  250. ^ Recommendation for the 2023-2024 Formula of COVID-19 vaccines in the U.S. (Report). FDA / CBER (VRBPAC). 16 June 2023. Retrieved 16 June 2023.
  251. PMID 34756186
    .
  252. .
  253. .
  254. .
  255. .
  256. .
  257. from the original on 8 December 2020. Retrieved 24 July 2021.
  258. ^ .
  259. .
  260. ^ "Nonclinical Evaluation Report: BNT162b2 [mRNA] COVID-19 vaccine" (PDF). Australian Department of Health: Therapeutic Goods Administration. Archived (PDF) from the original on 28 March 2023. Retrieved 25 March 2023.
  261. ^
    S2CID 246287912
    .
  262. .
  263. ^ "World Health Organization (WHO)". 17 September 2018. Archived from the original on 4 October 2023. Retrieved 19 September 2023.
  264. ^ McDonald J (23 December 2021). "Increase in COVID-19 VAERS Reports Due To Reporting Requirements, Intense Scrutiny of Widely Given Vaccines". FactCheck.org. Archived from the original on 20 May 2022. Retrieved 20 May 2022.
  265. ^ Treating Post-Vac-Syndrome – DW – 11 Oct 2022. [1] Archived 17 April 2023 at the Wayback Machine
  266. ^ UKGM Spezialsprechstunde Post-Vax (Post-Vac Special Consultation). [2] Archived 4 May 2023 at the Wayback Machine
  267. ^ [3] Archived 8 March 2024 at the Wayback Machine ((in German)) Corona-Impfschäden: Uniklinik Marburg öffnet eigene Ambulanz 3 April 2023 Frankfurter Allgemeine
  268. PMID 35233819
    .
  269. ^ .
  270. ^ a b COVID-19 vaccines safety update (PDF) (Report). Archived (PDF) from the original on 3 August 2022. Retrieved 6 September 2022.
  271. S2CID 240234869
    .
  272. .
  273. ^ .
  274. .
  275. .
  276. .
  277. .
  278. ^ Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. (2020–2022). "Coronavirus Pandemic (COVID-19)". Our World in Data. Retrieved 28 March 2024.
  279. ^ Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, et al. (2020). "Coronavirus Pandemic (COVID-19)". Our World in Data. Retrieved 14 November 2023.
  280. PMID 33972767
    .
  281. ^ Richie H, Ortiz-Ospina E, Beltekian D, Methieu E, Hasell J, Macdonald B, et al. (1 September 2021). "Coronavirus (COVID-19) Vaccinations - Statistics and Research". Our World in Data. Archived from the original on 10 March 2021. Retrieved 26 January 2021.
  282. ^ "Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine". World Health Organization (WHO). 27 April 2020. Archived from the original on 30 April 2020. Retrieved 2 May 2020. It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. The World Health Organization (WHO) is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale.
  283. ^
    PMID 32109012
    .
  284. from the original on 9 June 2020. Retrieved 9 June 2020.
  285. ^ a b c Steenhuysen J, Eisler P, Martell A, Nebehay S (27 April 2020). "Special Report: Countries, companies risk billions in race for coronavirus vaccine". Reuters. Archived from the original on 15 May 2020. Retrieved 2 May 2020.
  286. ISSN 0307-1235. Archived from the original
    on 4 May 2020. Retrieved 3 May 2020.
  287. ^ "WHO, UN set out steps to meet world COVID vaccination targets". World Health Organization (WHO). 7 October 2021. Archived from the original on 31 December 2021. Retrieved 31 December 2021.
  288. ^ "COVID-19: WHO calls on countries to vaccinate 70% of their population by mid-2022". 29 December 2021. Archived from the original on 31 December 2021. Retrieved 31 December 2021.
  289. ^ "Covid-19 vaccinations: African nations miss WHO target". BBC. 31 December 2021. Archived from the original on 31 December 2021. Retrieved 31 December 2021.
  290. ^
    PMID 34391506
    .
  291. ^ Adhanom Ghebreyesus T (18 January 2021). "WHO Director-General's opening remarks at 148th session of the Executive Board". World Health Organization (WHO). Archived from the original on 12 November 2021. Retrieved 25 January 2021.
  292. ^ "U.S. pressured Brazil to ditch Russia's Sputnik V vaccine". The Brazilian Report. 15 March 2021. Archived from the original on 15 March 2021. Retrieved 21 March 2021.
  293. ^ Holmes O (16 February 2021). "Israel blocked Covid vaccines from entering Gaza, say Palestinians". The Guardian. Archived from the original on 16 February 2021. Retrieved 17 February 2021.
  294. ^ Rasgon A (4 February 2021). "Israel's Vaccine Success Unleashes a Debate on Palestinian Inequities". The New York Times. Archived from the original on 28 December 2021. Retrieved 17 February 2021.
  295. ^ Horton C (17 February 2021). "Taiwan Concerned China May Have Blocked Vaccine Purchase". Bloomberg. Archived from the original on 17 February 2021. Retrieved 17 February 2021.
  296. ^ "Playing Politics with Poverty: Sisi's COVID-19 Vaccine Strategy". Carnegie Endowment for International Peace. Archived from the original on 28 February 2021. Retrieved 25 February 2021.
  297. ^ Strazewski L (9 February 2021). "Dr. Fauci: Variants reveal COVID-19 vaccination as global job". American Medical Association. Archived from the original on 10 October 2021. Retrieved 4 March 2021.
  298. ^ Bergmark E, Wierson A (26 February 2021). "Opinion: Without a global vaccine plan, coronavirus variants could lead to untold number of deaths". CNN. Archived from the original on 19 October 2021. Retrieved 4 March 2021.
  299. ^ Blenkinsop P, Maclean W, Ellis A (10 March 2021). "Rich, developing nations wrangle over COVID vaccine patents". Reuters. Archived from the original on 11 March 2021. Retrieved 19 June 2021.
  300. ^ Macias AM, Breuninger K, Franck (5 May 2021). "U.S. backs waiving patent protections for Covid vaccines, citing global health crisis". CNBC. Archived from the original on 5 May 2021. Retrieved 5 May 2021.
  301. ^ Sánchez Nicolás E (11 June 2021). "Pressure builds on EU to back WTO vaccine-patent waiver". EUobserver. Archived from the original on 19 October 2021. Retrieved 14 June 2021.
  302. ^ "WHO says against proof of Covid-19 vaccination for international travel". South China Morning Post. 20 April 2021. Archived from the original on 3 May 2021. Retrieved 17 May 2021.
  303. from the original on 15 May 2021. Retrieved 17 May 2021.
  304. ^ Muniz B, Fonseca B, Fernandes L, Pina R (15 March 2021). "Brasil registra duas vezes mais pessoas brancas vacinadas que negras" [Brazil registers twice as many white people vaccinated as black people]. Agência Pública (in Brazilian Portuguese). Archived from the original on 15 March 2021. Retrieved 28 May 2021.
  305. ^ Schnirring L (17 May 2021). "UN agencies make urgent appeal for COVAX vaccine doses". CIDRAP. Archived from the original on 31 October 2021. Retrieved 15 June 2021.
  306. ^ "First Meeting of the Task Force on COVID-19 Vaccines, Therapeutics and Diagnostics for Developing Countries". World Health Organization (WHO). 30 June 2021. Archived from the original on 19 October 2021. Retrieved 5 July 2021.
  307. ^ Tapper J, McKie R (3 July 2021). "Vaccines 'outpaced by variants', WHO warns, as Delta now in 98 countries". The Guardian. Archived from the original on 21 October 2021. Retrieved 5 July 2021.
  308. S2CID 236457553
    .
  309. ^ Levin D (1 August 2021). "The U.S. is wasting vaccine doses, even as cases rise and other countries suffer shortages". The New York Times. Archived from the original on 9 August 2021. Retrieved 10 August 2021.
  310. ^ "Covid-19 vaccines: Why some African states can't use their vaccines". BBC News. 8 June 2021. Archived from the original on 14 November 2021. Retrieved 20 August 2021.
  311. ^ Das S (5 July 2021). "CoWIN goes global: India makes tech open source, 142 nations show interest". Business Standard India. Archived from the original on 25 March 2022. Retrieved 25 March 2022.
  312. ^ "Aarogya Setu is now open source". pib.gov.in (Press release). 26 May 2020. Archived from the original on 26 June 2020. Retrieved 18 July 2023.
  313. ^ "G7 support for pharma monopolies is putting millions of lives at risk" (Press release). Amnesty International. 10 June 2021. Archived from the original on 19 October 2021. Retrieved 20 August 2021.
  314. ^ "Vaccine monopolies make cost of vaccinating the world against COVID at least 5 times more expensive than it could be" (Press release). Oxfam International. 29 July 2021. Archived from the original on 10 January 2022. Retrieved 20 August 2021.
  315. ^ Stiglitz J (15 December 2021). "If Olaf Scholz is serious about progress, he must back a patent waiver for Covid vaccines". The Guardian. Archived from the original on 15 December 2021. Retrieved 15 December 2021.
  316. ^ "Countries must not let another opportunity slip by to advance the global waiver on overcoming COVID-19 medical-tool monopolies". Médecins Sans Frontières (MSF)/Doctors Without Borders. 13 September 2021. Archived from the original on 10 October 2021. Retrieved 23 September 2021.
  317. ^ "MSF calls for no patents or profiteering on COVID-19 drugs and vaccines / No profiteering on COVID-19 drugs and vaccines, says MSF". Médecins Sans Frontières (MSF) International. Archived from the original on 26 November 2021. Retrieved 23 September 2021.
  318. ^ "Governments must act fast on consensus supporting historic move to suspend monopolies during pandemic / COVID-19: Governments must build consensus around waiver". Médecins Sans Frontières (MSF) International. Archived from the original on 23 October 2021. Retrieved 23 September 2021.
  319. S2CID 237199262
    .
  320. ^ "WHO slams wealthy nations' rush towards Covid booster shots while millions worldwide lack first jab". France 24. Agence France-Presse. 18 August 2021. Archived from the original on 2 November 2021. Retrieved 21 August 2021.
  321. ^ Kramer J (18 August 2021). "The U.S. plans to authorize boosters—but many already got a third dose". National Geographic. Archived from the original on 10 October 2021. Retrieved 21 August 2021.
  322. ^ "More than 140 former heads of state and Nobel laureates call on candidates for German chancellor to waive intellectual property rules for COVID-19 vaccines". Oxfam International (Press release). 14 September 2021. Archived from the original on 19 October 2021. Retrieved 22 September 2021.
  323. ^ Walker P (29 November 2021). "Nursing unions around world call for UN action on Covid vaccine patents". The Guardian. Archived from the original on 29 November 2021. Retrieved 29 November 2021.
  324. ^ Psaledakis D (22 September 2021). "Developing nations' plea to world's wealthy at U.N.: stop vaccine hoarding". Reuters. Archived from the original on 10 November 2021. Retrieved 29 September 2021.
  325. ^ Empresa Peruana de Servicios Editoriales S. A. EDITORA PERÚ. "Peru: President suggests global agreement at UN ensuring universal access to vaccines". Andina (in Spanish). Archived from the original on 30 October 2021. Retrieved 29 September 2021.
  326. S2CID 231946710
    .
  327. ^ "Additional Dose of mRNA COVID‑19 Vaccine for Patients Who Are Immunocompromised". U.S. Centers for Disease Control and Prevention (CDC). 13 August 2021. Archived from the original on 7 October 2021. Retrieved 16 August 2021.
  328. ^ "France plans rollout of Covid vaccine booster shots – but only for the vulnerable". France 24. 4 August 2021. Archived from the original on 22 October 2021. Retrieved 16 August 2021.
  329. ^ "Israel to offer 3rd COVID booster shot to older citizens". Associated Press. 29 July 2021. Archived from the original on 31 October 2021. Retrieved 16 August 2021.
  330. from the original on 9 October 2021. Retrieved 16 August 2021.
  331. ^ "UN analysis shows a link between lack of vaccine equity and widening poverty gap". UN News. 28 March 2022. Archived from the original on 12 April 2022. Retrieved 14 April 2022.
  332. ^ "DCVMN". Developing Countries Vaccine Manufacturers Network. Archived from the original on 26 April 2022. Retrieved 26 April 2022.
  333. (PDF) from the original on 28 August 2021. Retrieved 9 June 2021.
  334. ^ CDC (11 February 2020). "When You've Been Fully Vaccinated". U.S. Centers for Disease Control and Prevention (CDC). Archived from the original on 28 July 2021. Retrieved 29 April 2021.
  335. ^ a b "COVID vaccines: Widening inequality and millions vulnerable". United Nations. 19 September 2021. Archived from the original on 31 December 2021. Retrieved 30 October 2021.
  336. ^ "Impact of vaccine inequity on economic recovery". UN Development program. Archived from the original on 3 November 2021. Retrieved 30 October 2021.
  337. ^ Elliott L (5 October 2021). "IMF cuts global economic forecast as pandemic 'hobbles' growth". The Guardian. Archived from the original on 27 October 2021. Retrieved 6 October 2021.
  338. ^ "Refugees face dire consequences from COVID-19 underfunding, UNHCR warns". United Nations. 17 September 2021. Archived from the original on 30 October 2021. Retrieved 30 October 2021.
  339. ^ a b Azar A (4 February 2020). "Notice of Declaration under the Public Readiness and Emergency Preparedness Act for medical countermeasures against COVID-19". Archived from the original on 25 April 2020. Retrieved 22 April 2020.
  340. ^ Lintern S (2 December 2020). "Pfizer given protection from legal action over coronavirus vaccine by UK government". The Independent. Archived from the original on 5 May 2021. Retrieved 8 May 2021.
  341. ^ "Questions and Answers: Conditional Marketing Authorisation of COVID-19 Vaccines in the EU". European Commission. 11 December 2020. Question: What is the difference in liability between EU Conditional Marketing Authorisation vs Emergency Use Authorisations?. Archived from the original on 4 October 2021. Retrieved 29 December 2020.
  342. ^ "EMA recommends standard marketing authorizations for Comirnaty and Spikevax COVID-19 vaccines". European Medicines Agency. 16 September 2022. Archived from the original on 16 September 2022. Retrieved 7 October 2022.
  343. ^ Haahr T (7 September 2020). "COVID-19: MEPs want safe vaccines, full transparency and liability for companies". European Parliament. Ms. Gallina stressed negotiations with companies had been difficult but underlined that those companies developing and manufacturing COVID-19 vaccines would indeed be liable according to current laws, and if something goes wrong, they could be taken to court. This also goes for compensation for hidden defects. Archived from the original on 13 October 2021. Retrieved 29 December 2020.
  344. ^ "Investigation: Drugmaker 'bullied' Latin American nations". Al Jazeera. 11 March 2021. Archived from the original on 31 October 2021. Retrieved 15 June 2021.
  345. ^ Barcellos R (13 May 2021). "Carlos Murillo diz que cláusulas criticadas pelo Brasil valem em 110 países" [Carlos Murillo says critical clauses for Brazil are valid in 110 countries]. CNN Brasil (in Portuguese). Archived from the original on 28 June 2021. Retrieved 15 June 2021.
  346. ^ "Governor Ron DeSantis Petitions Florida Supreme Court for Statewide Grand Jury on COVID-19 Vaccines and Announces Creation of the Public Health Integrity Committee". www.flgov.com. Archived from the original on 14 December 2022. Retrieved 14 December 2022.
  347. ^ "Florida governor seeks grand jury investigation into Covid vaccines". www.theguardian.com. 13 December 2022. Archived from the original on 13 December 2022. Retrieved 14 December 2022.
  348. ^ "Blackwater founder Prince takes role in COVID vaccine venture". Reuters. 4 June 2021. Archived from the original on 9 October 2021. Retrieved 4 June 2021.
  349. ^ Lynas M (20 April 2020). "COVID: Top 10 current conspiracy theories". Alliance for Science. Retrieved 4 October 2021.
  350. ^ Burakovsky A (28 August 2021). "Russia's COVID-19 response slowed by population reluctant to take domestic vaccine". KRQE. Retrieved 20 September 2021.
  351. ^ "A Covid pass takes France by storm". WLFI News. Archived from the original on 20 September 2021. Retrieved 20 September 2021.
  352. ^ "MLB offers free tickets for COVID-19 vaccinations". Kron4. 4 June 2021. Retrieved 4 October 2021.
  353. ^ Gore D (10 May 2021). "Exploring the legality of COVID-19 vaccine mandates". factcheck.org. Retrieved 4 October 2021.
  354. .

Further reading

Vaccine protocols

External links